Red blood cell-derived Magnetic Immuno-Particle and Use thereof
Magnetic immune particles derived from red blood cells efficiently capture and remove disease-related substances, addressing inefficiencies in conventional detection methods and providing a safe treatment for infectious diseases and other conditions.
Patent Information
- Application Number
- KR1020230145964
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-10-28
- Filing Date
- 2023-10-27
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2043-10-27
AI Technical Summary
Conventional methods for detecting pathogens and disease-related substances in the body are inefficient, costly, and can cause adverse effects, while antibiotic treatments for infectious diseases are ineffective against superbugs and have harmful side effects.
Development of magnetic immune particles derived from red blood cells, which capture and remove various substances like pathogens, inflammatory cytokines, and cancer-related substances using a cell membrane and magnetic particles, allowing for detection and treatment through a magnetic field.
The magnetic immune particles provide a safe and efficient method for diagnosing and treating infectious diseases, inflammatory diseases, diabetes, and brain diseases by effectively capturing and removing target substances without causing side effects.
Smart Images

Figure 112023118736544-PAT00001_ABST
Abstract
Description
Technology Field
[0001] This relates to red blood cell-derived magnetic immune particles and their uses. Background Technology
[0002] Globally, pathogens, such as pathogenic microorganisms or antigens derived from them, infect water systems and humans, causing many diseases.
[0003] Conventional methods developed to detect pathogens present in the blood have had disadvantages such as long detection times or low detection efficiency. For example, cell culture methods and polymerase chain reaction (PCR), a gene detection method, are being developed to detect microorganisms (Korean Patent Publication No. 10-2018-0023545). Cell culture is a method for separating and identifying pathogenic and non-pathogenic viruses, and is determined by whether a cytopathic effect (CPE) occurs. Generally, it takes a long time, about 1 to 4 weeks, until a cytopathic effect is observed. Therefore, cell culture has low utility value in determining the presence of harmful microorganisms and preparing countermeasures. Furthermore, Polymerase Chain Reaction (PCR), a genetic diagnostic method that amplifies small amounts of DNA or RNA, offers superior sensitivity, specificity, and speed compared to cell culture methods, thereby overcoming their shortcomings. However, it has a drawback: if trace amounts of harmful microorganisms are present in the sample or if a significant amount is lost during the nucleic acid extraction process, PCR detection may yield a negative result. In other words, there is a possibility that microorganisms are present even if they are not detected by PCR. Additionally, fundamental problems with PCR include the difficulty of quantitative analysis and a high risk of false positives due to contamination. Meanwhile, the treatment of infectious diseases still largely relies on antibiotic administration. However, antibiotic administration has fatal drawbacks, such as causing blood cell depletion, hypersensitivity reactions, and neurotoxic side effects affecting the nervous system, heart, kidneys, and liver. Recently, the emergence of "super bacteria" resistant to antibiotics has led to a significant decline in the success rate of antibiotic-based treatments for infectious diseases. To address these problems, there is a need to develop a method for detecting or removing pathogens that is safe, has high detection efficiency, and does not cause side effects when administered into the body.
[0004] In addition, in addition to pathogenic substances such as pathogens, cancer-related substances such as inflammatory cytokines, blood glucose, extracellular vesicles derived from cancer cells or nucleic acids derived from tumor cells, and brain disease-related substances such as amyloid beta 42, amyloid beta 40, or tau protein can serve as markers for various diseases such as inflammatory diseases, diabetes, cancer, and brain diseases, or can cause or exacerbate the aforementioned various diseases. However, conventional technology requires the application of methods, materials, devices, kits, etc., corresponding to each of these various disease-related substances present in the body in order to detect them, and this results in problems such as high costs and reduced detection or analysis efficiency. Therefore, as a method capable of diagnosing, preventing, or treating various diseases by simply detecting or removing the various disease-related substances present in the body in a single manner, there is a need for a method capable of detecting or removing disease-related substances with a broad spectrum and high efficiency, but no such method has been developed to date.
[0006] Against this backdrop, the inventors have developed a magnetic immune particle derived from red blood cells. Since the magnetic immune particle derived from red blood cells contains a cell membrane derived from red blood cells, it can minimize adverse effects in vivo and can detect and remove various types of substances (e.g., pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances, etc.) from a sample with excellent efficiency. By confirming that it can be usefully utilized to diagnose, prevent, or treat various types of diseases such as infectious diseases, inflammatory diseases, diabetes, cancer, and brain diseases, the present invention has been completed. The problem to be solved
[0007] One aspect provides a magnetic immune particle comprising a cell membrane derived from red blood cells; and a magnetic particle attached to said cell membrane.
[0008] Another aspect is to provide a composition for detecting or removing pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, or brain disease-related substances containing the above-mentioned magnetic immune particles.
[0009] Another aspect is to provide a composition for diagnosing infectious diseases, inflammatory diseases, diabetes, cancer, or brain diseases comprising the above-mentioned magnetic immune particles.
[0010] Another aspect is to provide a method for detecting or removing pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, or brain disease-related substances present in a sample from said sample using said magnetic immune particles.
[0011] Another aspect is to provide a method for providing information necessary for the diagnosis of infectious diseases, inflammatory diseases, diabetes, cancer, or brain diseases using the aforementioned magnetic immune particles (or a method for diagnosing infectious diseases, inflammatory diseases, diabetes, cancer, or brain diseases).
[0012] Another aspect is to provide a method for preventing or treating infectious diseases, inflammatory diseases, diabetes, cancer, or brain diseases using the aforementioned magnetic immune particles.
[0013] Another aspect is to provide a kit or device utilizing the aforementioned magnetic immune particles.
[0014] Another aspect is to provide a method for manufacturing the above-mentioned magnetic immune particles.
[0016] Other objects and advantages of this application will become more apparent from the following detailed description, together with the appended claims and drawings. Anything not described in this specification is omitted, as it can be sufficiently recognized and inferred by those skilled in the art of this application or a similar art field. means of solving the problem
[0017] Each description and embodiment disclosed in this application may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application should not be considered limited by the specific descriptions provided below.
[0019] One aspect provides a magnetic immune particle comprising a cell membrane derived from red blood cells; and magnetic particles attached to said cell membrane.
[0020] The magnetic immune particles described above are formed by attaching magnetic particles to a red blood cell-derived cell membrane capable of capturing various substances. Specifically, as target substances for capture, they can capture various substances such as pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances. Furthermore, the magnetic immune particles that have captured the target substances can be separated or removed from a sample, such as blood, by a magnetic field. Accordingly, the magnetic immune particles can be used to detect, separate, or remove the target substances from a sample, such as blood. In this specification, the term "magnetic immune particles" may be used interchangeably with "magnetic nanoparticles," "magnetic nano-immune particles," "cell membrane-magnetic particle complexes," "red blood cell-derived magnetic immune particles," etc.
[0021] The technology proposed in this specification is characterized by 1) preparing magnetic immune particles in which magnetic particles are attached to a red blood cell-derived cell membrane, 2) bringing the magnetic immune particles into contact with a sample so that the target substance to be captured (e.g., pathogenic substance) present in the sample is captured by the magnetic immune particles, and 3) separating the magnetic immune particles that have captured the target substance from the sample by a magnetic field to detect the target substance to be captured in the sample or to remove the target substance to be captured from the sample.
[0022] In this specification, the term "attachment" may refer to a form located on the outside or inside of a cell membrane bilayer. For example, it may refer to a form in which magnetic particles are directly bound to the outside or inside of the cell membrane bilayer, or a form in which magnetic particles are absorbed into the cell membrane and captured (or embedded, or encapsulated), but is not limited thereto.
[0023] The above pathogenic substance may include one or more selected from the group consisting of bacteria, fungi, viruses, parasites, prions, and toxins, but may include any pathogenic substance capable of being captured by a cell membrane without limitation. The above pathogenic substance may cause an infectious disease in the body, such as malaria. In addition, the above pathogenic substance may include cells infected with the above pathogenic substance, such as cells infected with malaria larvae. In addition, the above pathogenic substance may include pathogens. The above pathogenic substance may include, but is not limited to, pathogenic substances present in biological samples (e.g., blood) isolated from a patient suffering from a disease (e.g., infectious disease, inflammatory disease, diabetes, cancer, brain disease, etc.).
[0024] In one embodiment, the pathogenic bacteria may be any type of Gram-positive or Gram-negative bacterium. More specifically, , Enterobacteriaceae, bacterial kingdom ( Enterobacteriaceae spp), Enterococcus kingdom ( Enterococcus spp), Citrobacter kingdom (Citrobacter spp), Staphylococcus bacteria kingdom ( Staphylococcus spp), Klebsiella bacterial kingdom ( Klebsiella spp), Pseudomonas kingdom ( Pseudomonas spp), Acinetobacter kingdom ( Acinetobacter spp), Salmonella kingdom ( Salmonella spp), Streptococcus kingdom ( streptococcus spp), Escherichia coli kingdom ( Escherichia spp), Mycobacterium kingdom ( Mycobacteriumspp), Mycoplasma kingdom ( Mycoplasma spp), Vibrio kingdom ( Vibrio spp ), Dysentery kingdom ( Shigella spp ), Campylobacter bacteria ( Campylobacter spp), Chlamydia ( Chlamydia It may include, but is not limited to, one or more selected from the group consisting of spp), and bacteria that have acquired antibiotic resistance.
[0025] In addition, in one embodiment, the pathogenic fungus is of the Candida kingdom ( Candida spp), Aspergillus fungal kingdom ( Aspergillus spp), Trichophyton kingdom ( Trichophyton spp), and Cladophiarophora kingdom ( Cladophialophora It may include one or more selected from the group consisting of spp), but is not limited thereto.
[0026] In addition, in one embodiment, the pathogenic virus may include, but is not limited to, one or more selected from the group consisting of Adenoviridae, Picornaviridae, Herpesviridae, Hepadnaviridae, Flaviviridae, Retroviridae, Orthomyxoviridae, Paramyxoviridae, Papovaviridae, Polyomavirus, Rhabdoviridae, and Togaviridae. More specifically, the pathogenic virus may include, but is not limited to, one or more selected from the group consisting of RSV (Respiratory syncytial virus), ZIKV (Zika virus), HCov229E (Human Coronavirus 229E), HCoV-OC43 (Human coronavirus OC43), CMV (Cytomegalovirus), SARS-CoV-1 (Severe acute respiratory syndrome coronavirus 1), SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), variants of SARS-CoV-2 (Alpha variant, Beta variant, Delta variant, etc.), Ebola virus, and Dengue virus.
[0027] Additionally, in one embodiment, the parasite may include malaria larvae, but is not limited thereto.
[0028] In addition, in one embodiment, the prion may include, but is not limited to, an infectious protein pathogen that causes infectious diseases including, scrapie, mad cow disease, Creutzfeldt-Jakob disease, etc.
[0029] In addition, in one embodiment, the toxin may include any substance having pathogenicity such as causing disease, and may include, but is not limited to, a pathogenic substance (e.g., antigen protein) derived from said pathogenic bacteria, fungi, viruses, or parasites. For example, the toxin may include, but is not limited to, LPS (Lipopolysaccharide, Endotoxin), ZIKV (Zika virus) Envelope Protein, SARS-CoV-2 Spike Protein, or SARS-CoV-2 variant virus Spike Protein (Alpha variant Spike Protein, Beta variant Spike Protein, or Delta variant Spike Protein).
[0030] The above inflammatory cytokines may be included without limitation as long as they are cytokines that cause or exacerbate inflammation, for example, the above inflammatory cytokines may include one or more selected from the group consisting of tumor necrosis factor-α (TNF-α), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin-1 beta (IL-1β), interleukin-1 alpha (IL-1α), interleukin 8 (IL-8), interferon gamma (IFN-γ), and granulocyte-macrophage colony-stimulating factor (GM-CSF), but are not limited thereto. The above inflammatory cytokines may include, but are not limited to, inflammatory cytokines present in biological samples (e.g., blood) isolated from patients suffering from diseases (e.g., infectious diseases, inflammatory diseases, diabetes, cancer, brain diseases, etc.).
[0031] The above blood glucose may include, but is not limited to, glucose present in biological samples (e.g., blood) separated from patients suffering from diseases (e.g., infectious diseases, inflammatory diseases, diabetes, cancer, brain diseases, etc.).
[0032] The above cancer-related substances may include cancer (tumor) cells (e.g., circulating tumor cells (CTCs), blood cancers (leukemia, myeloma), etc.), cancer-inducing substances, cancer metastasis-inducing substances, substances derived from cancer cells, cancer cell metabolites, metabolites resulting from the occurrence or progression of cancer disease, etc. For example, they may include extracellular vesicles derived from cancer cells, nucleic acids derived from cancer cells (e.g., circulating tumor cells, etc.), or combinations thereof, but are not limited thereto. The above cancer-related substances may also include cancer-related substances present in biological samples (e.g., blood) isolated from patients suffering from diseases (e.g., infectious diseases, inflammatory diseases, diabetes, cancer, brain diseases, etc.), but are not limited thereto.
[0033] The above brain disease-related substances may include brain disease-inducing substances, metabolites resulting from the occurrence or progression of brain disease, etc., and may include, for example, amyloid beta (Aβ) proteins (e.g., amyloid beta 42 (Aβ42), amyloid beta 40 (Aβ40), etc.), tau proteins, or combinations thereof, but are not limited thereto. The above amyloid beta proteins may include amyloid beta monomers, amyloid beta dimers, amyloid beta oligomers, amyloid beta plaques, etc., but are not limited thereto. The above brain disease-related substances may also include brain disease-related substances present in biological samples (e.g., blood) isolated from a patient suffering from a disease (e.g., infectious disease, inflammatory disease, diabetes, cancer, brain disease, etc.), but are not limited thereto.
[0034] In this specification, the term "capture" means that the substance to be captured binds to or connects with the magnetic immune particle. Specifically, the term "capture" may mean that the substance to be captured binds to or connects to the surface or interior of the cell membrane of the magnetic immune particle. In this specification, the term "capture" may be used interchangeably with terms such as "capture," "adsorption," "absorption," "binding," and "connection."
[0035] The above red blood cells or cell membranes derived from red blood cells may be derived from cells of one or more individuals selected from the group consisting of humans, primates such as monkeys, rodents such as rats and mice, ungulates such as horses, cattle, pigs, sheep, and goats, mammals such as horses, canids, and felines, birds, fish, reptiles, amphibians, crustaceans, and insects, but are not limited thereto. Since the cell membranes derived from red blood cells do not cause an immune rejection reaction when administered into the body, they have excellent safety when administered to the body.
[0036] In this specification, the term “cell membrane” refers to the cell membrane itself present in a cell, or a cell membrane separated from a cell by conventional methods, such as ultrasonic treatment, use of osmotic pressure difference, extrusion, etc. (specifically, a cell membrane in which its original form is maintained, a part or fragment of a cell membrane, a membrane formed by reassembling a part or fragment of a cell membrane, etc.).
[0037] The cell membrane derived from the above red blood cells may include, express, or overexpress one or more selected from the group consisting of a complement receptor (CR), a cluster of differentiation (CD) molecule, a glycophorin, a Duffy antigen receptor for chemokines (DARC), a glucose transporter (e.g., GLUT1 (Glucose transporter 1)), and a monocarboxylate transporter (MCT), but is not limited thereto. By expressing one or more selected from the group consisting of the complement receptor, the cluster of differentiation molecule, the glycophorin, the Duffy antigen receptor, the glucose transporter, and the monocarboxylate transporter, the cell membrane may uptake or endocytose magnetic particles or target substances, or bind to or attach to magnetic particles or target substances.
[0038] The cell membrane derived from the above red blood cells may contain, express, or overexpress complement receptors, differentiation cluster molecules, glycophorins, Duffy antigen receptors, glucose transporters, monocarboxylic acid receptors, or combinations thereof (e.g., CR1 (Complement receptor 1), GYPA (Glycophorin A), or combinations thereof). Here, overexpression may mean a state in which the expression of complement receptors, differentiation cluster molecules, glycophorins, Duffy antigen receptors, glucose transporters, monocarboxylic acid receptors, or combinations thereof (e.g., CR1, GYPA, or combinations thereof) is increased compared to the cell membrane of normal red blood cells.
[0039] Red blood cells having a cell membrane in which the above-mentioned complement receptor, differentiation cluster molecule, glycoporin, Duffy antigen receptor, glucose transporter, monocarboxylic acid receptor, or combination thereof (e.g., CR1, GYPA, or combination thereof) are overexpressed can be produced according to methods known in the art. For example, a method may be used in which genetic engineering is used to increase the expression of the complement receptor, differentiation cluster molecule, glycoporin, Duffy antigen receptor, glucose transporter, monocarboxylic acid receptor, or combination thereof (e.g., CR1, GYPA, or combination thereof) in a red blood cell precursor, and then the transformed red blood cell precursor is differentiated into red blood cells. Specifically, a method may be used to increase the copy number of said gene in the erythrocyte precursor by transfecting a foreign gene encoding a complement receptor, a differentiation cluster molecule, a glycoporin, a Duffy antigen receptor, a glucose transporter, a monocarboxylic acid receptor, or a combination thereof (e.g., CR1, GYPA, or a combination thereof) into an erythrocyte precursor cell, and said method may be performed by any method known in the art, for example, by introducing into an erythrocyte precursor cell a vector to which a gene encoding a complement receptor, a differentiation cluster molecule, a glycoporin, a Duffy antigen receptor, a glucose transporter, a monocarboxylic acid receptor, or a combination thereof (e.g., CR1, GYPA, or a combination thereof) is operably linked, which can replicate and function independently of the host or within the erythrocyte precursor cell, and said method may be performed, but is not limited thereto.
[0040] Red blood cells having a cell membrane overexpressing a complement receptor, a differentiation cluster molecule, a glycoporin, a Duffy antigen receptor, a glucose transporter, a monocarboxylic acid receptor, or a combination thereof (e.g., CR1, GYPA, or a combination thereof) can be produced through the above-described method, and according to a method of one embodiment of the present invention, a cell membrane can be separated from the red blood cells and magnetic particles can be attached to the separated cell membrane to produce a magnetic immune particle comprising a red blood cell-derived cell membrane overexpressing a complement receptor, a differentiation cluster molecule, a glycoporin, a Duffy antigen receptor, a glucose transporter, a monocarboxylic acid receptor, or a combination thereof (e.g., CR1, GYPA, or a combination thereof).
[0041] According to one embodiment, in the case of magnetic immune particles comprising an erythrocyte-derived cell membrane, it was confirmed that CR1, GYPA, or a combination thereof, which are surface molecules of the cell membrane, contribute significantly to the capture ability (detection or removal ability) of the magnetic immune particles for the target substances to be captured. Therefore, in the case of magnetic immune particles comprising an erythrocyte-derived cell membrane in which CR1, GYPA, or a combination thereof is overexpressed, the capture ability (detection or removal ability) for the target substances to be captured can be significantly increased.
[0042] In this specification, the term "magnetic particle" refers to a particle capable of responding to a magnetic field that can be easily absorbed by a cell, or can be bound, attached, introduced, incorporated, enclosed, or captured outside or inside a cell membrane. Specifically, the magnetic particles are selected from the group consisting of iron (Fe), nickel (Ni), cobalt (Co), manganese (Mn), bismuth (Bi), zinc (Zn), strontium (Sr), lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), ruthenium (Lu), copper (Cu), silver (Ag), gold (Au), cadmium (Cd), mercury (Hg), aluminum (Al), gallium (Ga), indium (In), thallium (Tl), calcium (Ca), barium (Ba), radium (Ra), platinum (Pt), and lead (Pd). It may include one or more magnetic elements, but is not limited thereto.
[0043] The magnetic element may be oxidized or surface-modified. Specifically, iron may be oxidized and incorporated into the magnetic immune particle in the form of iron oxide. The surface modification may be, but is not limited to, surface modification by metals, surface modification by functional groups such as carboxyl groups or amine groups, surface modification by proteins such as antibodies, streptavidin, or avidin, surface modification by carbohydrates, surface modification by polymers, or surface modification by lipids. The magnetic particle may be stabilized by the modification.
[0044] The above magnetic particles can be manufactured and used through known methods, or can be purchased commercially.
[0045] The above magnetic particles may be used as is or dispersed or suspended in a suitable solvent (e.g., buffer (PBS, saline, Tris-buffered saline, etc.), but are not limited thereto).
[0046] The magnetic particles described above have a small particle size, allowing each particle to possess a single magnetic domain. Consequently, they can exhibit superparamagnetism, possessing magnetic properties only in the presence of an external magnetic field. By creating magnetic immune particles using these superparamagnetic particles, the magnetic immune particles can be separated simply and easily by applying an external magnetic field. Separation by magnetic field application is not affected by surrounding environmental factors such as pH, temperature, and ions, thus offering excellent stability and sensitivity.
[0047] The magnetic particles may be selected from all particles that are magnetic and have a particle size capable of attaching to, entering, incorporating, or encapsulating a cell membrane capable of capturing the target substance. For example, the magnetic particles may be magnetic particles with an average particle size of about 100 to 500 or 100 to 300 nm, but are not limited thereto.
[0048] The magnetic particles may be contained in a solution. The magnetic particles may be attached to the cell membrane while contained in the solution. In one embodiment, the solution may include a medium, a buffer, or a combination thereof used to culture or differentiate cells, and may be the same as the medium of the magnetic immune particles.
[0049] The magnetic immune particle may include an outer surface including the cell membrane and an inner core including magnetic particles.
[0050] In the magnetic immune particle above, the inner core may include one or more, for example, one or more and 1,000,000 or fewer magnetic particles. Specifically, the inner core may include one or more and 100,000 or fewer, one or more and 10,000 or fewer, one or more and 1,000 or fewer, one or more and 100 or fewer, or one or more and 10 or fewer magnetic particles. The number of magnetic particles included in the inner core may be appropriately formed according to the size of the magnetic particles or the size of the magnetic immune particle. When the inner core includes two or more magnetic particles, the effect of capturing, detecting, or removing a target substance (e.g., a pathogenic substance) may be enhanced.
[0051] The average diameter of the above magnetic immune particles is about 1 nm to about 30,000 nm, about 10 nm to about 30,000 nm, about 50 nm to about 30,000 nm, about 100 nm to about 30,000 nm, about 200 nm to about 30,000 nm, about 300 nm to about 30,000 nm, about 400 nm to about 30,000 nm, about 500 nm to about 30,000 nm, about 1 nm to about 20,000 nm, about 10 nm to about 20,000 nm, about 50 nm to about 20,000 nm, about 100 nm to about 20,000 nm, about 200 nm to about 20,000 nm, about 300 nm to about 20,000 nm, about 400 nm to about 20,000 nm, about 500 nm to about 20,000 nm, about 1 nm to about 10,000 nm, about 10 nm to about 10,000 nm, about 50 nm to about 10,000 nm, about 100 nm to about 10,000 nm, about 200 nm to about 10,000 nm, about 300 nm to about 10,000 nm, about 400 nm to about 10,000 nm, about 500 nm to about 10,000 nm, about about 1 nm to about 5,000 nm, about 10 nm to about 5,000 nm, about 50 nm to about 5,000 nm, about 100 nm to about 5,000 nm, about 200 nm to about 5,000 nm, about 300 nm to about 5,000 nm, about 400 nm to about 5,000 nm, about 500 nm to about 5000 nm, 1 nm to about 1000 nm, about 10 nm to about 1000 nm, about 50 nm to about 1000 nm, about 100 nm to about 1000 nm, about 200 nm to about 1000 nm, about 300 nm to about 1000 nm, about 400 nm to about 1000 nm, about 500 nm to about 1000 nm, about 1 nm to about 500 nm, about 10 nm to about 500 nm, about 50 nm to about 500 nm, about 100 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 400 nm to about 500 nm,It may be about 150 nm to 350 nm, or about 200 nm to 300 nm, but is not limited thereto.
[0052] In the above-mentioned magnetic immune particles, the cell membrane may have the form of a vesicle. In this specification, the term "vesicle" may refer to a particle formed by the step of self-assembling or reassembling by extrusion of a cell membrane separated by the step of extracting (separating) the cell membrane from a cell by known techniques such as sonication, utilization of osmotic pressure difference, or extrusion.
[0053] An example of a manufacturing process for magnetic immune particles according to one embodiment is schematically illustrated in FIG. 1. Specifically, according to the Type 1 method of FIG. 1, red blood cells extracted from an individual are administered into a solution containing magnetic particles (e.g., blood, aqueous solution, purified water, buffer, culture medium, etc.) so that the magnetic particles are absorbed (or contained, integrated) into the cell through the phenomenon of cellular uptake, thereby producing red blood cells containing magnetic particles inside (e.g., magnetic immune cells) or red blood cell analogs. The red blood cells containing magnetic particles inside (e.g., magnetic immune cells) perform the original functions of red blood cells while simultaneously exhibiting magnetism or being affected by a magnetic field due to the magnetic particles contained inside.
[0054] In addition, magnetic immune particles can be formed using a cell membrane separated (or purified) from red blood cells according to the Type 2 method of FIG. 1. Specifically, a cell membrane can be separated (or purified) from red blood cells through a conventional method (e.g., using an osmotic pressure difference, ultrasonic treatment, extrusion, etc.), and the red blood cell-derived cell membrane and magnetic particles obtained therefrom can be extruded or ultrasonically treated to incorporate the magnetic particles into the red blood cell-derived cell membrane, thereby producing magnetic immune particles containing magnetic particles within the red blood cell-derived cell membrane. More specifically, to separate (or purify) the cell membrane from red blood cells, red blood cells can be administered into a low-osmotic solution, so that the low-osmotic solution moves into the red blood cells, causing the red blood cells to swell, and at the same time, pores can be formed in the cell membrane that allow organelles within the red blood cells to escape into the extracellular environment. Intracellular organelles that escape through the above pores can be removed separately using centrifugation, and only the cell-derived membrane can be separated (or purified), and the separated (or purified) red blood cell-derived cell membrane can be broken down into smaller sizes using ultrasonic treatment. Magnetic immune particles containing magnetic particles inside the cell membrane can be produced by mixing the red blood cell-derived cell membrane with magnetic particles and undergoing an extrusion or ultrasonic treatment process.
[0055] In addition, as shown in FIG. 1, magnetic immune particles can be formed using a cell membrane separated (or purified) from red blood cells according to the Type 3 method. Specifically, a cell membrane is separated (or purified) from red blood cells through a conventional method (e.g., using an osmotic pressure difference, extrusion, etc.), and the red blood cell-derived cell membrane obtained therefrom is mixed with magnetic particles, and then sonicated to incorporate the magnetic particles into the red blood cell-derived cell membrane, thereby producing magnetic immune particles containing magnetic particles inside the red blood cell-derived cell membrane.
[0056] The magnetic particles included in the magnetic immune particles may be monodispersed magnetic particles.
[0057] According to one embodiment, the magnetic immune particles may be obtained by extruding and / or ultrasonically treating a mixture of red blood cells or cell membranes separated from red blood cells and magnetic particles (e.g., monodisperse magnetic particles).
[0058] The monodispersity magnetic particles mentioned above may refer to a plurality of magnetic particles having a polydispersity index (PDI) of about 0.17 or less and having a high degree of uniformity in particle size (or uniformity). The polydispersity index is defined as the square of the value obtained by dividing the standard deviation of the particle size (e.g., diameter) by the average of the particle size (e.g., diameter), and represents a value between 0 and 1; the closer the value is to 0 (e.g., about 0.17 or less), the more uniform the particle size may be, indicating that the particles are monodispersity particles. Additionally, the monodispersity magnetic particles may have a diameter of about 200 to 300 nm. The above monodisperse magnetic particles can be manufactured by general methods known in the art, and any magnetic particle(s) that are of uniform size (or have a high degree of uniformity) (e.g., have a diameter distribution of about 200 to 300 nm and a polydispersity index of about 0.17 or less) and are not limited by the manufacturing method can be used as the above monodisperse magnetic particles without limitation.
[0059] Specifically, the magnetic particles may be magnetic particle(s) having a polydispersity index of about 0.17 or less, about 0.1 or less, about 0.05 or less, about 0.03 or less, about 0.02 or less, greater than 0 to 0.17 or less, greater than 0 to 0.1 or less, greater than 0 to 0.05 or less, greater than 0 to 0.03 or less, greater than 0 to 0.02 or less, about 0.01 to 0.03, or about 0.02 (e.g., monodisperse magnetic particle(s)).
[0060] According to one embodiment, in the case of magnetic immune particles obtained by extruding and / or sonicating a mixture of red blood cells or cell membranes separated from red blood cells and monodisperse magnetic particle(s), the capture ability (detection ability or removal ability) for pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, or brain disease-related substances may be further increased compared to magnetic immune particles prepared using polydisperse magnetic particles (e.g., polydisperse magnetic particle(s) with non-uniform particle sizes having a polydispersity index greater than about 0.17).
[0061] The above magnetic immune particles can perform functions similar to red blood cells because they contain cell membrane components of red blood cells (lipid bilayer, membrane proteins, receptors, etc.) in their outer membrane. Additionally, the above magnetic immune particles may exhibit magnetism or be affected by magnetic fields due to magnetic particles contained within them.
[0063] Another aspect provides a composition for detecting or removing a target substance for capture, comprising the magnetic immune particles described above. The target substance for capture may include one or more selected from the group consisting of pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances. The pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances are as described above.
[0064] Another aspect provides a composition for diagnosing infectious diseases, inflammatory diseases, diabetes, cancer, or brain diseases comprising the above-mentioned magnetic immune particles.
[0065] In this specification, the term "detection" may include determining whether a target substance is present in a sample or detecting a target substance present in a sample.
[0066] In this specification, the term "removal" means separating and removing a target substance present in a sample from the sample.
[0067] The magnetic immune particles described above utilize a red blood cell-derived cell membrane capable of capturing the target substance, and can bind to the target substance or capture the target substance into the cell membrane due to the characteristics of the red blood cell from which the cell membrane is derived. Additionally, the magnetic immune particles that have captured the target substance can be collected or concentrated into a magnetic field region by applying a magnetic field, thereby being separated from the sample. Based on this principle, a composition containing the magnetic immune particles can be used to detect the target substance within a sample, remove the target substance from a sample, or diagnose or treat a disease in an individual.
[0068] In the case of conventional magnetic immune particles using targeting substances (e.g., antibodies), binding to pathogenic substances was possible by forming a targeting substance capable of binding to pathogenic substances on the surface or inside the magnetic particle. Therefore, without accurate information on specific antigens of the pathogenic substances to be targeted, pathogenic substances cannot be effectively targeted, and there are significant difficulties in targeting multiple types of pathogenic substances simultaneously. In addition, since antibodies must be used, there were problems in that synthesis was very difficult and costly.
[0069] However, since the above-mentioned magnetic immune particles can use red blood cells isolated from the body or cell membranes derived therefrom as they are, they have the advantage of being able to capture various types of unknown target substances (e.g., pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, brain disease-related substances, etc.) at once by utilizing the system and characteristics of the red blood cells themselves, so they can be usefully utilized for the detection or removal of various substances.
[0070] The above composition can rapidly detect or remove contaminants (e.g., bacteria, fungi, viruses, other microorganisms, toxins (e.g., endotoxins), contaminant compounds, etc.) present in trace amounts in various foods, hygiene products, environmental samples, including drinking water and beverages, and thus can be used for safety assessments of foods, hygiene products, environmental samples, etc. Additionally, the above composition can detect or remove contaminants present in biological samples.
[0071] The above diagnostic composition can be used to diagnose infectious diseases, inflammatory diseases, diabetes, cancer, or brain diseases in an individual by detecting substances captured by the magnetic immune particles (e.g., pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, brain disease-related substances, etc.).
[0072] In this specification, the term "diagnosis of disease" may include determining whether an individual currently or previously has a specific disease, or determining whether an individual has been infected with a substance capable of causing a specific disease.
[0073] The above infectious disease may include, but is not limited to, one or more selected from the group consisting of systemic or local infections (e.g., pathogenic bacterial or viral infections), inflammation, sepsis, and poisoning by toxins. Additionally, any disease that occurs as a result of infection with the aforementioned target substance (e.g., pathogenic substance) is included without limitation. Specifically, the above infectious disease may include, but is not limited to, one or more selected from the group consisting of malaria, mycobacterial tuberculosis, pneumonia, food poisoning, tetanus, typhoid fever, diphtheria, syphilis, leprosy, chlamydia infection, smallpox, influenza, mumps, measles, chickenpox, Ebola, rubella, coronavirus infection, scrapie, mad cow disease, bacteremia, and Kritzveld-Jakob disease. The above infectious diseases may include, but are not limited to, infectious diseases that a patient with another disease (e.g., inflammatory disease, diabetes, cancer, brain disease, etc.) has additionally contracted or may contract.
[0074] The above-mentioned inflammatory diseases include systemic inflammatory response, cytokine release syndrome (e.g., cytokine storm), atopic dermatitis, encephilitis, inflammatory enteritis, chronic obstructive pulmonary disease, septicemic shock, pulmonary fibrosis, undifferentiated spondyloarthrosis, undifferentiated arthropathy, arthritis, inflammatory osteolysis, (chronic) inflammatory disease caused by viral or bacterial infection, colitis, inflammatory bowel disease, type 1 diabetes, rheumatoid arthritis, reactive arthritis, osteoarthritis, psoriasis, scleroderma, osteoporosis, atherosclerosis, myocarditis, endocarditis, pericarditis, cystic fibrosis, Hashimoto's thyroiditis, Graves' disease, leprosy, syphilis, Lyme disease, borreliosis, neuroborreliosis, tuberculosis, sarcoidosis, lupus, discoid lupus, It may include, but is not limited to, one or more selected from the group consisting of chilblain lupus, lupus nephritis, systemic lupus erythematosus, macular degeneration, uveitis, irritable bowel syndrome, Croesia, Sjögren's syndrome, fibromyalgia, chronic fatigue syndrome, chronic fatigue immunodeficiency syndrome, myalgic encephalomyelitis, amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. The above inflammatory diseases may include, but are not limited to, inflammatory diseases that a patient with another disease (e.g., infectious disease, diabetes, cancer, brain disease, etc.) has additionally contracted or may contract.
[0075] The above diabetes may include, but is not limited to, diabetes that has additionally developed or may develop in patients with other diseases (e.g., infectious diseases, inflammatory diseases, cancer, brain diseases, etc.).
[0076] The above-mentioned cancer is a collective term for diseases caused by cells that possess aggressive characteristics, such as dividing and growing while disregarding normal growth limits; invasive characteristics, such as infiltrating surrounding tissues; or metastatic characteristics, such as spreading to other parts of the body. The above-mentioned cancer may include both solid and non-solid cancers. For example, the above-mentioned cancer may include, but is not limited to, one or more selected from the group consisting of blood cancer, breast cancer, ovarian cancer, cervical cancer, colon cancer, lung cancer, liver cancer, brain cancer, esophageal cancer, prostate cancer, pancreatic cancer, thyroid cancer, colorectal cancer, and kidney cancer. The above-mentioned cancer may also include, but is not limited to, cancers that have been or may be additionally contracted by patients suffering from other diseases (e.g., infectious diseases, inflammatory diseases, diabetes, brain diseases, etc.).
[0077] The above brain disease may be, for example, a degenerative brain disease, but is not limited thereto. Specifically, the above brain disease may include, but is not limited to, Alzheimer's disease or Parkinson's disease. The above brain disease may also include, but is not limited to, brain diseases that a patient with another disease (e.g., infectious disease, inflammatory disease, diabetes, cancer, etc.) has additionally contracted or may contract.
[0078] The above composition may further include opsonins. The opsonins may include, but are not limited to, one or more selected from the group consisting of MBL (Mannose binding lectin), FCN-1 (Ficolin-1), FCN-2 (Ficolin-2), FCN-3 (Ficolin-3), CL-10 (collectin-10), CL-11 (collectin-11), C3b, C1q (complement component 1q), immunoglobulins, antibodies, C4b, surfactant protein A, surfactant protein D, pentraxins, and C-reactive protein.
[0079] According to one embodiment, the magnetic immune particle included in the composition may have its capture ability (detection or removal ability) for the target substance (e.g., pathogenic substance) further enhanced by the opsonin. In particular, compared with other opsonins, specific opsonins such as MBL, FCN-1, FCN-2, FCN-3, CL-10, and CL-11 may further enhance the capture ability (detection or removal ability) of the magnetic immune particle for the target substance (e.g., pathogenic substance).
[0080] The above composition may further include, but is not limited to, solvents, binders, lubricants, disintegrants, buffers, suspending agents, isotonic agents, viscosity modifiers, carriers, dispersants, lubricants, excipients, stabilizers, pH modifiers, preservatives, etc.
[0081] Among the terms or elements mentioned in the above composition, those mentioned in the description of the magnetic immune particles are understood to be the same as those mentioned in the description of the magnetic immune particles above.
[0083] Another aspect provides a method for detecting or removing a target substance present in a sample from the sample, comprising the steps of: contacting and mixing the magnetic immune particles with the sample; and applying a magnetic field to the mixed sample. The target substance may include one or more selected from the group consisting of pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances. The pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances are as described above.
[0084] Another aspect provides a method for providing information necessary for diagnosing a disease (or a method for diagnosing a disease), comprising the steps of: contacting and mixing the magnetic immune particles with a sample separated from an individual; and applying a magnetic field to the mixed sample.
[0085] Another aspect provides a method for preventing or treating a disease in an individual, comprising the steps of: contacting and mixing the magnetic immune particles with a sample separated from the individual (e.g., blood); applying a magnetic field to the mixed sample to remove the magnetic immune particles from the sample; and re-injecting the sample from which the magnetic immune particles have been removed back into the individual.
[0086] The above diseases may include infectious diseases, inflammatory diseases, diabetes, cancer, or brain diseases. The above infectious diseases, inflammatory diseases, diabetes, cancer, or brain diseases are as described above.
[0087] In the above method, the sample may be one or more selected from the group consisting of biological samples separated from the body of an animal (including or not including humans) (e.g., blood (e.g., whole blood), plasma, serum, lymph fluid, cerebrospinal fluid, etc., or cells, or tissues), drinking water (e.g., groundwater, tap water, bottled water, purified water, spring water, etc.), various foods, various sanitary products that act directly on the body, tableware, kitchenware, environmental samples (e.g., soil, seawater, river water, etc.), but is not limited thereto, and may be any object requiring detection and / or removal of the target substance to be captured. The sample may be a fluid itself or may be in the form of a suspension suspended in a suitable medium (e.g., purified water, sterile buffer, etc.).
[0088] The step of mixing the magnetic immune particles by contacting them with a sample may be performed in vitro and may include the step of culturing the magnetic immune particles and the sample together in vitro. In this step, the magnetic immune particles may bind (i.e., capture) the target substance present in the sample.
[0089] The step of culturing in vitro can be performed under normal conditions using a medium, buffer solution, saline solution, drinking water, the biological sample itself, etc., which are commonly used for cell culture. For example, it may include a step of culturing for about 1 second to 96 hours, about 1 second to 48 hours, about 1 second to 24 hours, for example, about 1 second to 12 hours, about 1 second to 6 hours, about 1 second to 120 minutes, or about 1 second to 60 minutes at a temperature of about 0 to 40°C or about 2 to 38°C.
[0090] In addition, the step of applying the magnetic field may be performed outside the body.
[0091] The above method may further include a step of separating (or removing) magnetic immune particles from the sample using the applied magnetic field (magnetic force) after the step of applying a magnetic field to the mixed sample. At this time, the separated magnetic immune particles may include magnetic immune particles that have bound to the target substance in the sample, as well as magnetic immune particles that have not bound to any substance. This step may be performed in vitro, and through this step, the target substance and magnetic immune particles may be removed from the sample.
[0092] A method for providing information necessary for the diagnosis of the above disease (or a method for diagnosing the disease) may further include a step of detecting and / or analyzing a substance bound to or captured by the magnetic immune particles. Additionally, a method for providing information necessary for the diagnosis of the above disease (or a method for diagnosing the disease) may further include a step of determining or predicting the type of disease of an individual providing a sample through the information obtained in the step of detection and / or analysis, or determining information for said determination or prediction. For example, if the substance bound to or captured by the magnetic immune particles is analyzed to be the pathogenic substance and its amount is analyzed to be above a certain standard, it can be determined or predicted that the individual providing the sample has contracted the infectious disease or is likely to contract it. Additionally, for example, if the substance bound to or captured by the magnetic immune particles is analyzed to be the inflammatory cytokine and its amount is analyzed to be above a certain standard, it can be determined or predicted that the individual providing the sample has contracted the inflammatory disease or is likely to contract it. In addition, for example, if the substance bound to or captured by the magnetic immune particle is analyzed to be blood glucose and the amount is analyzed to be above a certain standard, it can be determined or predicted that the individual who provided the sample has or is likely to have diabetes. In addition, for example, if the substance bound to or captured by the magnetic immune particle is analyzed to be a cancer-related substance and the amount is analyzed to be above a certain standard, it can be determined or predicted that the individual who provided the sample has or is likely to have cancer. In addition, for example, if the substance bound to or captured by the magnetic immune particle is analyzed to be a brain disease-related substance and the amount is analyzed to be above a certain standard, it can be determined or predicted that the individual who provided the sample has or is likely to have brain disease.
[0093] The above-mentioned prevention or treatment method may further include, after the step of applying a magnetic field to the mixed sample or separating (or removing) magnetic immune particles from the sample using the applied magnetic field (magnetic force), the step of injecting the sample from which the magnetic immune particles have been removed back into the body of the individual that provided the sample. At this time, the magnetic immune particles removed from the sample may include not only magnetic immune particles that have bound to the target substance within the sample but also magnetic immune particles that have not bound to any substance. Therefore, the sample injected back into the body of the individual may be one from which both the target substance and the magnetic immune particles have been removed.
[0094] The above method may further include a step of analyzing a substance captured by magnetic immune particles separated (or removed) from the sample. The analysis may be performed through means, methods, or devices commonly used for the analysis of the captured substance.
[0095] In the above method, to facilitate the measurement of magnetic immune particles, the magnetic immune particles may be obtained using cells (cell membranes) and / or magnetic particles labeled with a detectable labeling substance. The labeling substance may be any substance detectable by conventional methods (small molecule compounds, proteins, poly / oligopeptides, etc.) and may be one or more selected from the group consisting of, for example, fluorescent substances, luminescent substances, etc.
[0096] The above method may further include the step of introducing or injecting one or more selected from the group consisting of opsonin, blood, and plasma before applying the magnetic field. The opsonin may include, but is not limited to, one or more selected from the group consisting of MBL (Mannose binding lectin), FCN-1 (Ficolin-1), FCN-2 (Ficolin-2), FCN-3 (Ficolin-3), CL-10 (collectin-10), CL-11 (collectin-11), C3b, C1q (complement component 1q), Immunoglobulins, antibodies, C4b, surfactant protein A, surfactant protein D, pentraxins, and C-reactive protein. According to one embodiment, in the above method, the capture ability (detection or removal ability) for a target substance (e.g., pathogenic substance) may be further enhanced by introducing or injecting the opsonin. In particular, compared to other opsonins, specific opsonins such as MBL, FCN-1, FCN-2, FCN-3, CL-10, and CL-11 can further enhance the capture ability (detection or removal ability) of the magnetic immune particles for target substances (e.g., pathogenic substances).
[0097] The blood or plasma may be blood or plasma separated from the individual that provided the sample or another individual (e.g., another person). For example, the blood or plasma may be separated from the individual that provided the sample before or after contracting a disease, separated from another individual (e.g., another person) that was infected with a specific pathogenic substance, or separated from another individual (e.g., another person) that received a vaccine against a specific pathogenic substance. The blood or plasma may be rich in antibodies or opsonins to further enhance the capture ability (detection or removal ability) of the self-immunizing particles against the target substance (e.g., pathogenic substance).
[0098] In the above method, the step of introducing or injecting one or more selected from the group consisting of opsonin, blood, and plasma can be performed at any stage prior to applying a magnetic field. For example, one or more selected from the group consisting of opsonin, blood, and plasma may be added to the magnetic immune particles or sample and mixed before the step of mixing the magnetic immune particles and the sample, or one or more selected from the group consisting of opsonin, blood, and plasma may be additionally added and mixed during or after the step of mixing the magnetic immune particles and the sample.
[0099] The above-mentioned individual may be a human or an animal other than a human (e.g., mammals, etc.). The above-mentioned method may be performed by applying a magnetic immune particle-based hemodialysis or magnetic immune particle-based extracorporeal circulation method in vitro.
[0100] The term "prevention" in this specification refers to any act of blocking the occurrence of a disease in advance, suppressing a disease, or delaying its progression.
[0101] The term "treatment" in this specification refers to both therapeutic treatment and preventive or preventive measures. It also refers to any act that improves, alleviates, or beneficially alters the symptoms of a disease.
[0102] The above method may be implemented in the form of a kit comprising the magnetic immune particles or a device utilizing the magnetic immune particles. The kit or device may be, but is not limited to, the magnetic immune particle-based hemodialysis kit or device, or the magnetic immune particle-based extracorporeal blood circulation kit or device. Additionally, the kit or device may be implemented in the form of a fluid device (e.g., a microfluidic device) or may include a fluid device (e.g., a microfluidic device).
[0103] According to one embodiment, the method may be performed by a hemodialysis kit or device, or an extracorporeal blood circulation kit or device.
[0104] Schematic diagrams of the above kit or device (e.g., a hemodialysis kit or device, or an extracorporeal blood circulation kit or device) are shown in FIGS. 6 and FIGS. 9, but are not limited thereto.
[0105] Specifically, the kit or device (e.g., a hemodialysis kit or device, or an extracorporeal blood circulation kit or device) may include a reaction unit and a magnetic field generating unit.
[0106] The above reaction section may refer to a part into which the magnetic immune particles and the sample are brought into contact to mix, culture, or react, or into which a reaction product is introduced after the magnetic immune particles and the sample come into contact and react. In the above kit or device, the magnetic immune particles may be contained in the reaction section, or may be applied to the reaction section in the form of a reaction product after reacting with the sample beforehand, or may be provided separately from the reaction section, or may be provided in the form of a dispersion dispersed in a suitable medium (e.g., a buffer). In the above reaction section, the magnetic immune particles may bind (i.e., capture) a target substance present in the sample.
[0107] The magnetic field generating unit may refer to a part that generates a magnetic field. For example, the magnetic field generating unit may include one or more means capable of applying a magnetic field, such as a magnet (e.g., an electromagnet by electromagnetic induction, a permanent magnet, etc.). The magnetic field generating unit may be included in the reaction unit, provided separately from the reaction unit, or integrally provided in all or part of the reaction unit. If the magnetic field generating unit exists separately from the reaction unit, the reaction unit and the magnetic field generating unit may be connected by a channel through which fluid can move. When magnetic particles attached to magnetic immune particles move toward the magnet of the magnetic field generating unit due to the magnetic field generated by the magnetic field generating unit, the magnetic immune particles can be separated from the sample. At this time, the separated magnetic immune particles may include not only magnetic immune particles bound to the target substance within the sample but also magnetic immune particles that have not bound to any substance. Therefore, both the target substance and the magnetic immune particles can be removed from the sample in the magnetic field generating unit.
[0108] There are no particular restrictions on the shape of the reaction unit and / or magnetic field generating unit, whether integrated or separately provided, and it may have various shapes such as a well shape, a plate shape, or a channel shape. There are also no particular restrictions on the number of each of the reaction unit and / or magnetic field generating unit, whether integrated or separately provided, and there may be one or more of each. For example, if the reaction unit and the magnetic field generating unit are provided separately, one or more, for example, 1 to 10 reaction units may be connected to 1 to 10 magnetic field generating units, or if the reaction unit and the magnetic field generating unit form an integral structure, there may be 1 to 10 integral reaction units and magnetic field generating units, but this is not limited thereto.
[0109] The kit or device may include one or more injection ports connected to a reaction port into which a sample (in a fluid state, such as blood), magnetic immune particles (e.g., in a dispersion state), other additional components (e.g., opsonin, blood or plasma other than the sample), or reactants thereof are injected. The other side of the injection port not connected to the reaction port may be directly connected to an individual or to a separated sample, thereby allowing the sample to be injected through the injection port. Additionally, magnetic immune particles may be injected through the other side of the injection port not connected to the reaction port. Furthermore, additional components such as opsonin, blood or plasma other than the sample may be injected through the other side of the injection port not connected to the reaction port. The injection port may include one or more pumps or be connected to one or more pumps. One or more selected from the sample, magnetic immune particles, other additional components, and reactants thereof may be injected into the reaction port by means of the pump through the injection port.
[0110] The above kit or device may further include one or more discharge units connected to the magnetic field generating unit for discharging magnetic immune particles captured by the magnetic field. In this case, the magnetic immune particles separated from the sample discharged through the discharge unit may include not only magnetic immune particles bound to the target substance to be captured within the sample, but also magnetic immune particles that have not bound to any substance. The discharge unit may further include a detection unit comprising a detection means capable of detecting the substance captured by the discharged magnetic immune particles.
[0111] In the above kit or device, magnetic immune particles may be separated from the sample by the magnetic field in the magnetic field generating unit and collected or concentrated separately. The magnetic immune particles may include all magnetic immune particles that have captured or have not captured the target substance. In this case, the magnetic immune particles are not discharged and may be filtered, collected, concentrated, or removed within the magnetic field generating unit or in a capture unit connected to the magnetic field generating unit.
[0112] The above kit or device may further include a sample discharge section.
[0113] The above sample discharge unit may refer to a part where a separated sample is discharged by applying a magnetic field to the sample. There may be one or more of the above sample discharge units. A sample separated by moving to one location by applying a magnetic field while in a fluid flow state, such as a sample from which magnetic immune particles have been removed, may be discharged through the above sample discharge unit and concentrated or separated separately. The above magnetic immune particles may include all magnetic immune particles that have captured or have not captured the target substance. Therefore, the sample discharged through the above sample discharge unit may have both the target substance and the magnetic immune particles removed.
[0114] In the above kit or device, the sample discharge unit may be connected to the injection unit or to an individual. Accordingly, the sample from which magnetic immune particles have been removed, discharged through the sample discharge unit, can be injected again through the injection unit to repeat the process of removing the target substance within the sample, thereby more effectively removing any target substance that has not been completely removed. Additionally, the sample from which magnetic immune particles have been removed, discharged through the sample discharge unit, can be injected back into the individual. The magnetic immune particles may include all magnetic immune particles that have either captured or have not captured the target substance. Therefore, the sample injected back into the individual may have both the target substance and the magnetic immune particles removed.
[0115] Another aspect provides a method for manufacturing magnetic immune particles comprising the steps of: mixing a red blood cell or a cell membrane separated from a red blood cell with a magnetic particle; and extruding and / or ultrasonically treating the mixture obtained in the mixing step.
[0116] The magnetic particles may be monodisperse magnetic particles. The monodisperse magnetic particles may have a polydispersity index of about 0.17 or less.
[0117] The cell membrane, the magnetic particle, the magnetic immune particle, the monodisperse magnetic particle, the polydisperse index, and the method for manufacturing the magnetic immune particle are as described above.
[0118] The method of separating the cell membrane from the above red blood cells is not particularly limited and can be performed by general methods known in the art. For example, a cell membrane separated from red blood cells can be obtained by treating a solution containing red blood cells with a low osmotic pressure (after which centrifugation may be performed), but is not limited thereto. In addition, a process of treating the cell membrane separated from red blood cells with ultrasound of about 10 to 30 kHz and about 100 to 200 W for about 1 to 30 minutes may be further performed, but is not limited thereto.
[0119] The above mixture may be a mixture of a solution (e.g., a suspension) containing the red blood cells or cell membranes separated from the red blood cells and a solution (e.g., a suspension) containing the magnetic particles. Accordingly, the mixture may be the red blood cells or cell membranes separated from the red blood cells, and a solution (e.g., a suspension) containing the magnetic particles.
[0120] Extruding the above mixture may be performed, for example, by passing the mixture through one or more filters having a pore size of about 0.05 to 1 μm while applying pressure, but is not limited thereto, and the extrusion may be performed by an extruder, extrusion equipment, extrusion kit, etc., which are generally known in the art.
[0121] The above mixture can be ultrasonically treated by methods and conditions generally known in the art, and the magnetic particles may be combined or attached to the red blood cells or cell membranes separated from red blood cells present in the mixture, or the magnetic particles may be incorporated into the red blood cells or cell membranes separated from red blood cells, solely by ultrasonically treating the mixture without performing extrusion on the mixture.
[0122] Extruding or ultrasonically treating the above mixture may be performed optionally either or both processes, and if both processes are performed, the two processes may be performed simultaneously or sequentially without restriction on the order.
[0123] Through the step of extruding and / or sonicating the above mixture, one or more of the magnetic particles may be combined or attached to the red blood cell or cell membrane separated from the red blood cell, or one or more of the magnetic particles may be incorporated into the red blood cell or cell membrane separated from the red blood cell, thereby obtaining the magnetic immune particles.
[0124] Among the terms or elements mentioned in the above method, kit, and device, those mentioned in the description of the magnetic immune particles and composition are understood to be the same as those mentioned in the description of the magnetic immune particles and composition above. Effects of the invention
[0125] According to one aspect, the erythrocyte-derived magnetic immune particles include a cell membrane derived from erythrocytes, thereby minimizing in vivo side effects. Furthermore, due to the characteristics of the erythrocytes from which the cell membrane is derived, various types of substances (e.g., pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances, etc.) can be detected and removed from a sample with excellent efficiency. In addition, since the magnetic immune particles include magnetic particles, the magnetic immune particles can be easily separated by applying a magnetic field, allowing for more effective detection and removal of the various types of substances. When the magnetic immune particles are used for treatment, the possibility of injecting the particles into the body can be minimized, thereby significantly reducing in vivo side effects. Consequently, the magnetic immune particles can be usefully utilized for diagnosing, preventing, or treating various types of diseases, such as infectious diseases, inflammatory diseases, diabetes, cancer, and brain diseases. Brief explanation of the drawing
[0126] FIG. 1 is a schematic diagram showing a method for generating magnetic immune particles according to one embodiment. FIG. 2 is a transmission electron microscope (TEM) image showing magnetic immune particles generated according to one embodiment. The left side shows the magnetic particles used in one embodiment, and the right side shows the magnetic immune particles generated according to one embodiment. FIG. 3 shows pathogenic bacteria (A: MRSA and B: ESBL(+) of magnetic immune particles according to one embodiment) E.coli This is a figure showing the capture ability (detection or removal ability) for ) (HL60(N): neutrophil-derived magnetic immune particle; U937(M): macrophage-derived magnetic immune particle; hHSEC: human liver endothelial cell-derived magnetic immune particle; hRBC-MNVs: erythrocyte-derived magnetic immune particle). FIG. 4 is a figure showing the capture ability (detection or elimination ability) of magnetic immune particles against viruses (A: CMV and B: RSV) according to one embodiment (HL60(N): neutrophil-derived magnetic immune particle; U937(M): macrophage-derived magnetic immune particle; hHSEC: human liver endothelial cell-derived magnetic immune particle; hRBC-MNVs: erythrocyte-derived magnetic immune particle). FIG. 5 is a figure showing the capture ability (detection or removal ability) of magnetic immune particles for virus-derived antigen proteins (A: ZIKV E Protein and B: SARS-CoV-2 S Protein) according to one embodiment (HL60(N): neutrophil-derived magnetic immune particle; U937(M): macrophage-derived magnetic immune particle; hHSEC: human liver endothelial cell-derived magnetic immune particle; hRBC-MNVs: erythrocyte-derived magnetic immune particle). FIG. 6 is a schematic diagram showing a magnetic immune particle-based extracorporeal circulation device according to one embodiment. FIG. 7 shows antibiotic-resistant and susceptible bacteria (MRSA, VISA, etc.) present in a sample through an extracorporeal circulation device based on red blood cell-derived magnetic immune particles according to one embodiment. S. aureus , ESBL(+) E.coli Carbapenem-resistant E.coli , E.coli This is a graph showing the result of removing ). FIG. 8 is a graph showing the results of removing endotoxins (LPS) present in a sample through an extracorporeal circulation device based on erythrocyte-derived magnetic immune particles according to one embodiment. FIG. 9 is a schematic diagram showing a magnetic immune particle-based extracorporeal circulation device connected to an animal model according to one embodiment. FIG. 10 is a graph showing the results of removing pathogenic substances present in the in vivo blood of an animal infected with pathogenic bacteria using an erythrocyte-derived magnetic immune particle-based extracorporeal circulation device according to one embodiment (A: level of MRSA removal present in the in vivo blood of an MRSA-infected animal; B: Carbapenem-resistant E.coli Carbapenem-resistant substances present in the blood of infected animals E.coli Removal level; C: Carbapenem-resistant E.coli Level of endotoxin (LPS) clearance present in the in vivo blood of infected animals). FIG. 11 is a graph showing the survival rate of an animal infected with pathogenic bacteria as a result of removing pathogenic substances present in the in vivo blood of said animal using an erythrocyte-derived magnetic immune particle-based extracorporeal circulation device according to one embodiment (A: survival rate of an animal infected with MRSA; B: Carbapenem-resistant E.coli Survival rate of infected animals). FIG. 12 is a graph showing the results of removing Interleukin 6 (IL-6) present in a sample through an extracorporeal circulation device based on red blood cell-derived magnetic immune particles according to one embodiment. FIG. 13 is a graph showing the results of removing pro-inflammatory cytokines present in the in vivo blood of an animal infected with pathogenic bacteria using an erythrocyte-derived magnetic immune particle-based extracorporeal circulation device according to one embodiment (A: level of removal of pro-inflammatory cytokines present in the in vivo blood of an MRSA-infected animal; B: Carbapenem-resistant E.coli Levels of clearance of pro-inflammatory cytokines present in the in vivo blood of infected animals). FIG. 14 is a figure showing the capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles for blood glucose in a blood sample (A) and the capture ability (detection or removal ability) of pathogenic bacteria in a high blood glucose blood sample (B) according to one embodiment. FIG. 15 is a figure showing the pattern of reduction in capture ability (detection or removal ability) against various pathogens of red blood cell-derived magnetic immune particles in which cell membrane surface molecules (CR1 and / or GYPA) are inactivated according to one embodiment (RBC-MNVs: red blood cell-derived magnetic immune particles; CR1 blocked RBC-MNVs: red blood cell-derived magnetic immune particles in which CR1 is inactivated; GYPA blocked RBC-MNVs: red blood cell-derived magnetic immune particles in which GYPA is inactivated; GYPA & CR1 blocked RBC-MNVs: red blood cell-derived magnetic immune particles in which GYPA and CR1 are inactivated; MNPs: magnetic particles not containing a cell membrane surface). FIG. 16 is a figure showing the results of analyzing the capture ability (detection or removal ability) of erythrocyte-derived magnetic immune particles against pathogenic substances when said erythrocyte-derived magnetic immune particles are injected together with opsonin into a sample containing pathogenic substances according to one embodiment (A: injection of erythrocyte-derived magnetic immune particles together with opsonin into a TBS buffer containing pathogenic bacteria; B: injection of erythrocyte-derived magnetic immune particles together with opsonin into a TBS buffer containing a virus or virus-derived antigen protein; C: injection of erythrocyte-derived magnetic immune particles together with opsonin into a blood sample containing pathogenic bacteria). FIG. 17 is a figure showing the capture ability (detection or removal ability) of cancer-related substances (extracellular vesicles derived from cancer cell lines) present in human plasma and blood samples by erythrocyte-derived magnetic immune particles according to one embodiment. FIG. 18 is a figure showing the capture ability (detection or removal ability) of erythrocyte-derived magnetic immune particles for cancer-related substances (tumor cell-derived nucleic acids) according to one embodiment (A: capture ability (detection or removal ability) of erythrocyte-derived magnetic immune particles for normal cell-derived nucleic acids and tumor cell-derived nucleic acids; B: capture ability (detection or removal ability) of human erythrocyte-derived magnetic immune particles and mouse erythrocyte-derived magnetic immune particles for tumor cell-derived nucleic acids). FIG. 19 is a graph showing the recovery rate (A) and the purity (B) of the recovered nucleic acids by an elution solution of normal cell-derived nucleic acids and tumor cell-derived nucleic acids captured by red blood cell-derived magnetic immune particles according to one embodiment. FIG. 20 is a figure showing the capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles for a brain disease (Alzheimer's) related substance (amyloid beta 42) according to one embodiment. FIG. 21 is a graph showing the results of removing brain disease (Alzheimer's) related substances (A: tau protein; B: amyloid beta 40; C: amyloid beta 42) present in a sample through an extracorporeal circulation device based on red blood cell-derived magnetic immune particles according to one embodiment. FIG. 22 is a graph showing the diameters of monodisperse magnetic particles and polydisperse magnetic particles according to one embodiment. FIG. 23 is a figure showing the capture ability (detection or removal ability) of monodisperse magnetic immune particles and polydisperse magnetic immune particles for cancer-related substances (A: nucleic acid derived from circulating tumor cells; B: extracellular vesicle derived from cancer cell lines) according to one embodiment. FIG. 24 is a figure showing the capture ability (detection or removal ability) of monodisperse magnetic immune particles and polydisperse magnetic immune particles for brain disease (Alzheimer's) related substances (amyloid beta 40, amyloid beta 42, tau protein) according to one embodiment. Specific details for implementing the invention
[0127] The present invention is to be explained more specifically below through examples and experimental examples, but these are merely illustrative and are not intended to limit the scope of the invention. It is obvious to those skilled in the art that the examples and experimental examples described below may be modified without departing from the essential essence of the invention.
[0129] Example 1. Preparation of red blood cell-derived magnetic immune particles
[0130] Magnetic immune particles were synthesized using a human red blood cell model found in in vivo human blood. Red blood cells were obtained from the Red Cross (South Korea) and blood from donors who voluntarily agreed to participate (UNISTIRB-20-44-A). The red blood cells were placed in approximately 1 mL of a mixture of PBS (pH 7.2, Biosesang, South Korea) and distilled water (Biosesang, South Korea) at a concentration of approximately 25% v / v, with about 10 6The cells were inoculated to a quantity of 100, subjected to hypotonic treatment at 4°C for 1 hour, centrifuged at 4°C for 5 minutes (Centrifuge 5424R, Eppendorf, Germany), and prepared in 1× PBS. Additionally, the cell membranes separated (purified) by hypotonic treatment were subjected to sonication (Q700 Ultra-Sonicator, Qsonica, USA) at 4°C, 20 kHz, and 150 W for approximately 10 minutes to break the cell membranes into smaller units. Subsequently, the sonicated erythrocyte-derived cell membranes were extruded with magnetic particles using an Avanti mini extruder (Avanti Polar Lipids, Alabaster, AL, USA) with 1 μm, 0.4 μm, and 0.2 μm pore size track-etched membrane filters to prepare magnetic immunoparticles. Specifically, as in the type 2 method shown in Fig. 1, the prepared cell membrane and magnetic particles (about 0.5 mg / mL) were mixed and extruded to prepare magnetic immune particles in which the magnetic particles were embedded inside the cell membrane. As the magnetic particles, iron oxide magnetic particles (Carboxyl-Adembeads 200 nm, Ademtech, France) with an average particle size of about 100 to 300 nm (specifically, about 200 nm) and surface modified with carboxylic acid were used.
[0131] As a result, as shown in Fig. 2, through transmission electron microscopy (TEM) imaging, it was confirmed that magnetic immune particles with an average diameter of about 150 to 350 nm (specifically, about 250 nm) (right side of Fig. 2) were generated, in which magnetic particles were embedded in the red blood cell-derived cell membrane.
[0133] Experimental Example 1. Evaluation of the capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles against pathogenic substances
[0134] In order to determine whether the red blood cell-derived magnetic immune particles prepared in Example 1 above can capture (detect or remove) various pathogenic substances, including pathogens present in the blood, a human blood sample was randomly inoculated with pathogenic substances, and after injecting the red blood cell-derived magnetic immune particles, a magnetic field was applied to measure the change in the concentration of the pathogenic substances in the blood sample.
[0136] 1.1. Evaluation of the capture ability (detection or elimination ability) of red blood cell-derived magnetic immune particles against pathogenic bacteria
[0137] The capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles against pathogenic bacteria was evaluated.
[0138] Specifically, in approximately 1 mL of anticoagulant-treated human blood (Red Cross, South Korea) sample, MRSA (Methicillin Resistant), a Gram-positive bacterium Staphylococcus aureus ) or ESBL(+), a Gram-negative bacterium E.coli (Extended-Spectrum Beta-Lactamases Producing Escherichia coli ) is, about 10 4The sample was inoculated to a concentration of CFU / mL and cultured at approximately 37°C for about 10 minutes. After the culture was finished, the erythrocyte-derived magnetic immune particles prepared in Example 1 were injected into the blood sample to achieve a final concentration of approximately 100 to 200 μg / mL of the magnetic immune particles. Subsequently, after a reaction at approximately 37°C for about 20 minutes, the magnetic immune particles in the blood sample were fixed at a specific location using a magnet so that they would not be included in the supernatant. Then, the supernatant was collected, and the CFU (colony forming unit) of bacteria in the supernatant was checked. Specifically, the supernatant (about 100 μL) was diluted in about 900 μL of physiological saline and plated onto LB agar medium using a microbial analyzer (EDDY JET2, IUL micro, USA). After incubation at about 37°C for about 24 hours, the CFU of bacteria produced on the LB agar medium was measured using a microbial colony counter (Sphereflash colony counter and zone reader, IUL micro, USA). A sample in which the bacteria were inoculated and cultured in a blood sample in the same manner as described above, but without the injection of the erythrocyte-derived magnetic immune particles, was used as a control. The level of reduction in the CFU value of bacteria measured in the experimental group was calculated as a percentage (%) relative to the CFU value of bacteria measured in the control group, and the capture rate (or removal rate, %) of the erythrocyte-derived magnetic immune particles against the bacteria was evaluated. In addition, neutrophil-derived magnetic immune particles using a neutrophil (HL60)-derived cell membrane prepared by the same method as in Example 1; macrophage-derived magnetic immune particles using a macrophage (U937)-derived cell membrane; and human liver endothelial cell-derived magnetic immune particles using a human liver endothelial cell (hHSEC)-derived cell membrane were used as a control group.
[0139] As a result, as shown in Fig. 3, it was confirmed that the red blood cell-derived magnetic immune particles prepared in Example 1 can capture and detect or remove pathogenic bacteria in blood samples, including MRSA and ESBL(+) E.coli It was confirmed that it exhibits a significantly superior capture rate (approximately 60 to 90%) even against bacteria with antibiotic resistance such as. In particular, compared to the neutrophil-derived magnetic immune particles, the macrophage-derived magnetic immune particles, and the human liver endothelial cell-derived magnetic immune particles, the erythrocyte-derived magnetic immune particles [show] MRSA and ESBL(+) E.coli It was confirmed that the capture ability (detection or removal ability) for pathogenic bacteria such as [ ] is superior.
[0141] 1.2. Evaluation of the capture ability (detection or elimination ability) of erythrocyte-derived magnetic immune particles against viruses
[0142] The capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles against viruses was evaluated.
[0143] Specifically, about 1 mL of anticoagulated human blood (Red Cross, South Korea) sample containing CMV (cytomegalovirus) or RSV (respiratory syncytial virus), about 10 4The sample was inoculated to a concentration of PFU / mL and cultured at approximately 37°C for about 10 minutes. After the culture was finished, the erythrocyte-derived magnetic immune particles prepared in Example 1 were injected into the blood sample to achieve a final concentration of approximately 200 μg / mL. Subsequently, after a reaction at approximately 37°C for about 20 minutes, the magnetic immune particles within the blood sample were fixed at a specific location using a magnet to prevent them from being included in the supernatant. The supernatant was then collected, and the amount of viral RNA in the supernatant was measured. Nucleic acids were extracted from the virus present in the supernatant using a QIAmp viral RNA mini kit (QIAGEN, Germany), and the extracted nucleic acids were amplified using SYBR PCR master mix (Toyobo, Japan) and Real-time PCR (CFX connect, BIO-RAD, USA) to measure the amount of RNA. A sample in which the virus was inoculated and cultured in the same manner as described above, but without the injection of the erythrocyte-derived magnetic immune particles, was used as a control. The capture rate (or removal rate, %) of the erythrocyte-derived magnetic immune particles against the virus was evaluated by calculating the level of reduction in the amount of viral RNA measured in the experimental group as a percentage (%) based on the amount of viral RNA measured in the control group. In addition, neutrophil-derived magnetic immune particles using a neutrophil (HL60)-derived cell membrane; macrophage-derived magnetic immune particles using a macrophage (U937)-derived cell membrane; and human liver endothelial cell-derived magnetic immune particles using a human liver endothelial cell (hHSEC)-derived cell membrane, prepared by the same method as in Example 1, were used as a comparison group.
[0144] As a result, as shown in Fig. 4, it was confirmed that the erythrocyte-derived magnetic immune particles prepared in Example 1 can capture and detect or remove pathogenic viruses in blood samples (capture rate: about 60 to 80%). In particular, compared to the neutrophil-derived magnetic immune particles, the macrophage-derived magnetic immune particles, and the human liver endothelial cell-derived magnetic immune particles, it was confirmed that the erythrocyte-derived magnetic immune particles have superior capture ability (detection or removal ability) against pathogenic viruses such as CMV and RSV.
[0146] 1.3. Evaluation of the capture ability (detection or elimination ability) of erythrocyte-derived magnetic immune particles against virus-derived antigens
[0147] The capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles against virus-derived antigens was evaluated.
[0148] Specifically, about 1 mL of anticoagulated human blood (Red Cross, South Korea) sample was inoculated with ZIKV (Zika virus) Envelope Protein (ZIKV E Protein) or SARS-CoV-2 Spike Protein (SARS-CoV-2 S Protein) at a concentration of about 1 μg / mL, and the red blood cell-derived magnetic immune particles prepared in Example 1 were injected at a concentration of about 200 μg / mL. Then, a magnet was used to fix the magnetic immune particles in the blood sample at a specific location so that the magnetic immune particles were not included in the supernatant, and then the supernatant was collected and the concentration of the virus-derived antigen in the supernatant was measured. The concentration of the above virus-derived antigen was measured by enzyme-linked immunosorbent assay (ELISA), using a Zika virus (strain Zika SPH2015) Envelope Protein (ZIKV-E) ELISA Kit (Sinobio, China) or a SARS-CoV-2 Spike protein ELISA kit (ab274342, abcam, USA). Based on the concentration of the virus-derived antigen in the blood sample prior to the injection of the magnetic immune particles, the reduction level of the virus-derived antigen concentration measured in the supernatant was calculated as a percentage (%), and the capture rate (or removal rate, %) of the erythrocyte-derived magnetic immune particles against the virus-derived antigen was evaluated. In addition, neutrophil-derived magnetic immune particles utilizing a neutrophil (HL60)-derived cell membrane and macrophage-derived magnetic immune particles utilizing a macrophage (U937)-derived cell membrane, prepared by the same method as in Example 1; and human liver endothelial cell-derived magnetic immune particles utilizing cell membranes derived from human liver endothelial cells (hHSEC) were used as a control group.
[0149] As a result, as shown in Fig. 5, it was confirmed that the erythrocyte-derived magnetic immune particles prepared in Example 1 can capture and detect or remove virus-derived antigen proteins in blood samples (capture rate: about 50 to 70%). In particular, compared to the neutrophil-derived magnetic immune particles, the macrophage-derived magnetic immune particles, and the human liver endothelial cell-derived magnetic immune particles, it was confirmed that the erythrocyte-derived magnetic immune particles have superior capture ability (detection or removal ability) for virus-derived antigen proteins such as ZIKV E Protein and SARS-CoV-2 S Protein.
[0151] 1.4. Evaluation of the capture (detection or elimination) ability of erythrocyte-derived magnetic immune particles against 137 species of bacteria found in fecal samples used in Fecal Microbiota Transplantation (FMT)
[0152] In the same manner as in Experimental Example 1.1 above, the capture ability (detection or removal ability) of the erythrocyte-derived magnetic immune particles prepared in Example 1 above against 137 species of bacteria (see Table 1) found in fecal samples used for Fecal Microbiota Transplantation (FMT) was evaluated, and the results are shown in Table 1 below.
[0153] bacteria Removal rate (%) bacteria Removal rate (%) Fusobacterium perfoetens 99.99014 Blautia argi 99.76875 Anaerobiospirillum succiniciproducens 100 Blautia obeum 99.99168 Phocaeicola plebeius 99.98403 Anaerotignum faecicola 99.99667 Mediterranea massiliensis 99.97913 Flavonifractor plautii 99.97116 Fusobacterium mortiferum 99.95149 Collinsella intestinalis 99.81064 Faecalibacterium prausnitzii 99.96941 Bacteroides cellulolyticus 98.33818 Mucispirillum schaedleri 99.99316 Allobaculum dung beetle 99.93248 Phocaeicola coprophilus 99.99233 Fournierella massiliensis 99.96307 Brachyspira hampsonii 100 Haemophilus hemoglobinophilus 99.73614 Bacteroides uniformis 99.9847 Hungatella xylanolytica 99.98594 Phocaeicola coprocola 99.9615 Ruminococcus lactaris 99.94898 Common phocaeicola 99.97373 Other 99.97268 Corynebacterium amycolatum 100 Catenibacterium mitsuokai 97.99739 Sutterella massiliensis 99.8365 Clostridium methylpentosum 99.96376 Lachnospira eligens 99.97393 Flintibacer butyricus 99.98363 Lachnoclostridium pacaense 99.98789 Peptostreptococcus canis 99.96395 Corynebacterium lowii 100 Pasteurella stomatis 100 Prevotella scatcorea 99.9932 Mediterraneibacter glycyrrhizinilyticus 99.92791 Blautia marasmi 99.94649 Helicobacter winghamensis 100 Peptacetobacter hiranonis 99.84061 Holdemanella biformis 98.94652 Lachnospira pectinoschiza 99.98531 Bacteroides faeces 99.98326 Kineothrix alysoides 99.96107 The unpopular dialer 99.98326 Bacteroides thetaiotaomicron 99.97833 Enterococcus fowleri 100 Lactobacillus rogosae 99.9878 Blautia schinkii 98.73838 Eubacterium rectale 99.97145 Blautia wexlerae 100 Paraprevotella clara 99.9821 Pseudoflavonifractor phocaeensis 100 Ruminococcus gnavus 99.93576 Desulfovibrio simplex 100 Intestinal roseburia 99.97928 Dog's scaly 99.96615 Pseudomonas matsuisoli 99.98258 Amedibacillus dolichus 99.96264 Corynebacterium confusum 100 Blood fluke 99.76724 Megamonas funicularis 98.34063 Enterococcus faecalis 100 Bacteroides suffocatus 99.98891 Monoglobus pectinolyticus 99.95674 Helicobacter canicola 100 Agathobaculus buttery-producing 99.96692 Winkia neui 100 Staphylococcus simulans 100 Aerococcus vaginalis 100 Enterococcus dispar 100 Roseburia inulinivorans 99.98123 Clay clay 100 Porphyromonas cangingivalis 99.86023 Hespellia porcina 100 Bacteroides koreensis 99.98575 Helicobacter biliary 100 Human rosebuds 99.99708 Prevotella copri 46.55614 Sutterella stercoricanis 99.99581 Caproiciproducens galactitolivorans 99.90683 Ant-like gemmiger 99.97684 Romboutsia sedimentorum 99.9634 Rotten sedges 99.98396 Dorea ant-producing 100 Parabacteroides murdae 99.98566 Klebsiella variicola 100 Blautia faeces 99.96416 Tyzzerella nexilis 99.66837 Eubacterium ventriosum 99.99581 Holdemania massiliensis 99.98198 Butyricicoccus pullicaecorum 99.964 Candidatus Pelagibacter ubiquitatum 100 Faecalimonas umbilicata 99.93603 Bifidobacterium catenulatum 99.93315 Escherichia fergusonii 99.96595 Campylobacter showae 99.97247 Staphylococcus felis 100 Erysipelatoclostridium ramosum 99.98034 Roseburia faeces 99.9843 Clostridium tertium 99.9827 Bacteroides pyogenes 99.93792 Peptococcus niger 99.9243 Helicobacter canis 100 Buchananella hordeovulneris 100 Bacteroides fragilis 99.95284 Eubacterium coprostanoligenes 99.8517 Parabacteroides distasonis 99.98583 Clostridium paraputrificum 100 Helicobacter pylori 100 Eubacterium ramulus 100 Staphylococcus intermedius 100 Long-chained dorea 100 Anaerostipes hadrus 99.9976 Demequina estuary 100 Phascolarctobacterium succinatutens 100 Streptococcus canis 100 Fusicatenibacter saccharivorans 99.98648 Lachnospira multipara 100 Clostridium spiroforme 99.98289 Anaerobic acetethylum 100 Alistipes shahii 99.95674 Anaerobutyricum hallii 100 Frederiksenia canicola 100 Coprococcus catus 100 Enterocloster clostridioformis 100 Nitrososphaera viennaensis 100 Bacteroides xylanisolvens 99.92538 Paludibacter propionicigenes 100 Long stick for the wall 100 Synechococcus rubescens 100 Oscillibacter ruminantium 99.98621 Sea cucumber 100 Corynebacterium auriscans 100 Campylobacter upsaliensis 100 Agathobaculum desmolans 100 Escherichia marmotae 100 Klebsiella pneumoniae 100
[0154] As a result, as shown in Table 1, the red blood cell-derived magnetic immune particles prepared in Example 1 above have a significantly superior capture ability (detection or removal ability) against various types of bacteria, and it was confirmed that they have a considerably broad spectrum in bacterial capture (detection or removal).
[0156] 2. Jeopardy
[0157] Pathogenic substances, such as pathogens and endotoxins present in a blood sample, were removed in vitro using an extracorporeal circulation device based on red blood cell-derived magnetic immune particles. Specifically, as shown in FIG. 6, the extracorporeal circulation device based on red blood cell-derived magnetic immune particles comprises: an injection section (sample injection section and magnetic immune particle injection section) into which blood contaminated with pathogenic substances and red blood cell-derived magnetic immune particles are injected; a reaction section (mixing fluid element section) into which the injected blood and magnetic immune particles are mixed and the pathogenic substances are captured (or bound) to the magnetic immune particles; a magnetic field generating section (magnetophoresis separation fluid element section) into which the magnetic immune particles into which the pathogenic substances are captured (or bound) (and magnetic immune particles into which the pathogenic substances are not captured (or bound)) are removed from the blood by a magnetic field; and an discharge section into which the blood from which the pathogenic substances and magnetic immune particles have been removed is discharged.
[0158] Specifically, in approximately 1 mL of anticoagulant-treated human blood (blood from a donor with a voluntary willingness to participate, UNISTIRB-20-44-A) sample, as a pathogenic substance, pathogenic bacteria ( Staphylococcus aureus ( S. aureus ), MRSA, Vancomycin-intermediate resistant S. aureus (VISA), Escherichia coli ( E. coli ), ESBL(+) E.coli (ESBL-producing E.coli ), or Carbapenem-resistant E.coli ; Approx. 10 4 CFU / mL) Alternatively, an endotoxin (Lipopolysaccharide: LPS; approximately 10 μg / mL) was inoculated and cultured at approximately 37°C for approximately 10 minutes. Additionally, a saline solution containing the red blood cell-derived magnetic immune particles prepared in Example 1 at a concentration of approximately 0.1 to 1 mg / mL was prepared. The blood sample after the culture was circulated using an extracorporeal circulation device at a rate of approximately 10 mL / hr, and the solution containing the red blood cell-derived magnetic immune particles was loaded into the extracorporeal circulation device at a rate of approximately 0.5 mL / hr. While the injected blood sample and the magnetic immune particle solution flowed through the reaction section (mixing fluid element section) and underwent a mixing process, the pathogenic substances in the blood sample and the magnetic immune particles bound together. While the blood sample containing the above conjugate passed through the magnetic field generating unit (magnetophoresis separation fluid element part), the conjugate (and magnetic immune particles not bound to pathogenic substances) were captured toward the magnet by the magnetic field and removed from the blood sample. The blood sample from which pathogenic substances and magnetic immune particles were removed was discharged and collected, and then re-injected into the extracorporeal circulation device. This process of removing pathogenic substances through erythrocyte-derived magnetic immune particle-based extracorporeal blood circulation was repeated for approximately 5 hours. Simultaneously, the concentration of pathogenic substances in the blood sample was measured at 1-hour intervals. Specifically, changes in bacterial concentration in the blood sample were confirmed by measuring the CFU of bacteria in the same manner as in Experimental Example 1.1, and changes in LPS concentration in the blood sample were measured using an enzyme-linked immunosorbent assay (ELISA), using an LPS ELISA kit (LS-F55757-1, LSbio, USA). In addition, an experimental group that was not injected with the above magnetic immune particles was used as a control group.
[0159] As a result, as shown in FIGS. 7 and 8, the red blood cell-derived magnetic immune particles prepared in Example 1 are resistant to pathogenic substances present in a sample such as blood, such as pathogens and endotoxins, for example, antibiotic-resistant and susceptible bacteria (e.g., MRSA, VISA, S. aureus , ESBL(+) E.coli Carbapenem-resistant E.coli , E.coli It was found that pathogenic substances such as pathogens and endotoxins (LPS) can be removed very effectively. In addition, it was found that even when using the above-mentioned extracorporeal circulation device, the capture ability (detection or removal ability) of the above-mentioned red blood cell-derived magnetic immune particles against pathogenic substances is fully exerted, and pathogenic substances such as pathogens and endotoxins can be sufficiently removed from the sample outside the body. In particular, when using the above-mentioned extracorporeal circulation device, the process of removing pathogenic substances from the sample using the above-mentioned red blood cell-derived magnetic immune particles can be repeated, so it was found that pathogenic substances such as pathogens and endotoxins present in the sample can be removed by more than about 90%, and up to 100%.
[0161] Experimental Example 3. Confirmation of removal of pathogenic substances in in vivo blood and therapeutic effects on infectious diseases using an extracorporeal circulation device based on red blood cell-derived magnetic immune particles.
[0162] An extracorporeal circulation device based on red blood cell-derived magnetic immune particles was applied to an animal model to confirm the removal effect of pathogenic substances, such as pathogens and endotoxins present in the blood, and the resulting treatment effect for infectious diseases. The method of removing pathogenic substances using the extracorporeal circulation device based on red blood cell-derived magnetic immune particles is the same as that described in Experimental Example 2 above; however, this experiment differs from Experimental Example 2 in that an in vivo evaluation was performed by directly connecting the extracorporeal circulation device based on red blood cell-derived magnetic immune particles to a rat animal model arbitrarily infected with pathogenic bacteria (see Fig. 9). The extracorporeal circulation device based on red blood cell-derived magnetic immune particles is as described in Experimental Example 2 above.
[0163] Specifically, as shown in Fig. 9, a normal Wistar rat (10 weeks old, male) was anesthetized, and a catheter was surgically inserted into the jugular vein. Through the catheter, MRSA (approx. 1 × 10⁶) was arbitrarily injected. 10 CFU) or Carbapenem-resistant E.coli (approx. 5 × 10 9 Rats were infected by injecting CFU. Additionally, a magnetic immune particle solution containing magnetic immune particles at a concentration of approximately 0.5 mg / mL, manufactured using the cell membranes of red blood cells derived from Wistar rats (8 weeks old, male), was prepared in saline solution. The infected rat was connected to the sample infusion port of the red blood cell-derived magnetic immune particle-based extracorporeal circulation device via the catheter, and blood from the infected rat was injected into the extracorporeal circulation device through the sample infusion port. Furthermore, the prepared magnetic immune particle solution was injected into the extracorporeal circulation device connected to the rat to perform the process of removing pathogenic substances through red blood cell-derived magnetic immune particle-based extracorporeal blood circulation. The blood, from which pathogenic substances and magnetic immune particles had been removed, was discharged through the discharge port of the extracorporeal circulation device and re-injected into the rat connected to the discharge port. Whole blood was collected from the rats at regular intervals to check for MRSA and Carbapenem-resistant compounds in the blood. E.coliChanges in the concentrations of endotoxin (LPS) and other substances were measured, and the survival rate of rats was measured. Changes in bacterial concentration in blood samples were confirmed by measuring the CFU of bacteria in the same manner as in Experimental Example 1.1 above, and changes in LPS concentration in blood samples were measured by enzyme-linked immunosorbent assay (ELISA), using an LPS ELISA kit (LS-F55757-1, LSbio, USA). In addition, an experimental group injected with an antibiotic (colistin) instead of the magnetic immune particles and an experimental group not injected with the magnetic immune particles were used as controls.
[0164] As a result, as shown in Fig. 10, MRSA or Carbapenem-resistant E.coli When erythrocyte-derived magnetic immune particle-based extracorporeal blood circulation is applied to rats infected with [specific pathogens] via the aforementioned extracorporeal circulation device, MRSA, Carbapenem-resistant [specific pathogens] in the blood of the infected rats E.coli It was confirmed that pathogenic substances such as , and endotoxins (LPS) were very effectively removed. In particular, when erythrocyte-derived magnetic immune particle-based extracorporeal blood circulation was applied to infected rats twice over two days using the aforementioned extracorporeal circulation device, the blood levels of MRSA, Carbapenem-resistant... E.coli It was confirmed that the removal efficiency of pathogenic substances significantly increased as the concentrations of endotoxins (LPS) and erythrocyte-derived magnetic immune particles dropped below the measurement limit. On the other hand, when an antibiotic (colistin) was injected instead of erythrocyte-derived magnetic immune particles, it was confirmed that while the concentration of bacteria in the blood of infected rats could be reduced, the concentration of endotoxins (LPS) in the blood of infected rats could not be reduced at all.
[0165] In addition, as shown in Fig. 11, when the survival rate of infected rats was measured, it was confirmed that the survival rate of infected rats increased significantly when the erythrocyte-derived magnetic immune particle-based extracorporeal blood circulation was applied through the extracorporeal circulation device. In particular, when the erythrocyte-derived magnetic immune particle-based extracorporeal blood circulation was applied to infected rats twice over two days, all infected rats survived for 7 days, showing a 100% survival rate. On the other hand, it was confirmed that the survival rate was significantly low in infected rats that were not injected with erythrocyte-derived magnetic immune particles and in infected rats that were injected with an antibiotic (colistin) instead of erythrocyte-derived magnetic immune particles, as all of them died within 3 days.
[0166] Through this experimental example, pathogenic substances such as pathogens (e.g., pathogenic bacteria or viruses, etc.) and endotoxins present in the blood within the body can be effectively removed by an extracorporeal blood circulation device or method using red blood cell-derived magnetic immune particles, and as a result, infectious diseases (e.g., MRSA, Carbapenem-resistant) can be treated more effectively than when antibiotics are used. E.coli such It was confirmed that it can treat pathogenic bacterial or viral infections, etc.
[0168] Experimental Example 4. Confirmation of removal of pro-inflammatory cytokines in the blood using an extracorporeal circulation device based on red blood cell-derived magnetic immune particles
[0169] Pro-inflammatory cytokines present in in vitro blood samples and in vivo blood of animal models infected with pathogenic bacteria were removed using an erythrocyte-derived magnetic immune particle-based extracorporeal circulation device. The method for removing pro-inflammatory cytokines from in vitro blood samples and in vivo blood using the erythrocyte-derived magnetic immune particle-based extracorporeal circulation device is the same as that described in Experimental Examples 2 and 3 above. The erythrocyte-derived magnetic immune particle-based extracorporeal circulation device is as described in Experimental Examples 2 and 3 above.
[0170] Specifically, in the same manner as in Experimental Example 2 above, blood samples collected from rat animals (Wistar, male, 8 weeks old) were inoculated with Interleukin 6 (IL-6) as a pro-inflammatory cytokine and cultured. Then, magnetic immune particles prepared using the cultured blood samples and the cell membranes of red blood cells derived from Wistar rats (8 weeks old, male) were injected into the extracorporeal circulation device to perform the process of removing Interleukin 6 through red blood cell-derived magnetic immune particle-based extracorporeal blood circulation. Afterward, the concentration of Interleukin 6 in the expelled blood samples was measured. Additionally, an experimental group that was not injected with the magnetic immune particles was used as a control group.
[0171] In addition, in the same manner as in Experimental Example 3 above, MRSA or Carbapenem-resistant rats were arbitrarily tested on normal Wistar rats. E.coliAfter infecting the rat by injecting [the substance], the infected rat was connected to the extracorporeal circulation device, and magnetic immune particles prepared using the blood of the infected rat and the cell membrane of red blood cells derived from a Wistar rat (8 weeks old, male) were injected into the extracorporeal circulation device to perform a process of removing pro-inflammatory cytokines through red blood cell-derived magnetic immune particle-based extracorporeal blood circulation. Afterward, the expelled blood was injected back into the rat connected to the extracorporeal circulation device. Whole blood was collected from the infected rats before and after performing the erythrocyte-derived magnetic immune particle-based extracorporeal blood circulation, and the concentrations of pro-inflammatory cytokines (tumor necrosis factor-α (TNF-α), interleukin 4 (IL-4), IL-6, interleukin-1 beta (IL-1β), granulocyte-macrophage colony-stimulating factor (GM-CSF)) in the blood were measured. In addition, an experimental group injected with an antibiotic (colistin) instead of the magnetic immune particles was used as a control group.
[0172] As a result, as shown in FIGS. 12 and 13, it was found that red blood cell-derived magnetic immune particles can very effectively remove pro-inflammatory cytokines present in samples such as blood. In particular, it was found that when using the extracorporeal circulation device based on the red blood cell-derived magnetic immune particles, it is possible to very effectively remove pro-inflammatory cytokines present in in vivo blood as well as blood samples outside the body. Furthermore, it was confirmed that in the case of infected rats injected with an antibiotic (colistin) instead of red blood cell-derived magnetic immune particles, the concentration of pro-inflammatory cytokines in the blood actually increased. Thus, it was confirmed that when using the extracorporeal blood circulation device or method utilizing the red blood cell-derived magnetic immune particles, pro-inflammatory cytokines in the blood can be removed more effectively than conventional antibiotic treatment methods, thereby demonstrating superior effects in alleviating symptoms (e.g., alleviating inflammation, alleviating cytokine storms, etc.) or treating inflammatory or infectious diseases.
[0174] Experimental Example 5. Evaluation of the capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles against blood glucose and pathogenic substances present in hyperglycemic blood.
[0175] To determine whether red blood cell-derived magnetic immune particles can capture (detect or remove) pathogenic substances, such as blood glucose and pathogenic bacteria present in hyperglycemic blood, blood samples to which glucose (D-glucose, Sigma-Aldrich, USA) was randomly added were inoculated with randomly pathogenic bacteria and cultured; then, red blood cell-derived magnetic immune particles were injected into the culture medium, and a magnetic field was applied to measure the changes in the concentrations of blood glucose and pathogenic bacteria within the blood samples.
[0176] Specifically, D-glucose was added to approximately 1 mL of a blood sample collected from rats (Wistar, male, 8 weeks old) to a concentration of approximately 400 to 450 mg / dL, and incubated at approximately 37°C for approximately 10 minutes. After incubation, MRSA was added to the blood sample at approximately 10 4 to 105 The sample was inoculated to a concentration of CFU / mL and cultured at approximately 37°C for about 10 minutes. After the culture was finished, magnetic immune particles prepared using the cell membranes of red blood cells derived from Wistar rats (8 weeks old, male) were injected into the blood sample to achieve a final concentration of magnetic immune particles of approximately 100 to 200 μg / mL. Subsequently, after a reaction at approximately 37°C for about 20 minutes, the magnetic immune particles in the blood sample were fixed at a specific location using a magnet to prevent them from being included in the supernatant. The supernatant was then collected, and the concentrations of D-glucose and MRSA in the supernatant were measured. Additionally, the process of reinjecting the magnetic immune particles into the supernatant to induce a reaction and then separating the magnetic immune particles using a magnet was repeated several times. Changes in MRSA concentration were confirmed by measuring the CFU of bacteria in the same manner as in Experimental Example 1.1 above, and changes in D-glucose concentration were measured using a commercial blood glucose meter (ACCU-CHEK, Roche, Switzerland). In addition, an experimental group that was not injected with the magnetic immune particles was used as a control group.
[0177] As a result, as shown in Figure 14, it was confirmed that the concentrations of D-glucose and MRSA pathogens present in hyperglycemic blood samples decreased significantly compared to the control group as the removal process using red blood cell-derived magnetic immune particles was repeated.
[0178] Through this experimental example, it was found that red blood cell-derived magnetic immune particles exhibit significantly superior blood glucose detection and removal effects. Therefore, red blood cell-derived magnetic immune particles (e.g., an extracorporeal blood circulation device or method utilizing red blood cell-derived magnetic immune particles) can detect blood glucose in the blood outside the body and remove blood glucose through blood purification. Furthermore, by re-injecting the blood with removed glucose back into the body, they can be effectively utilized to lower blood glucose levels in patients with hyperglycemia or diabetes. Consequently, it was found that red blood cell-derived magnetic immune particles can be effectively utilized for the diagnosis, prevention, or treatment of diabetes (e.g., alleviation of symptoms). Additionally, since red blood cell-derived magnetic immune particles can very effectively remove pathogenic substances, such as pathogenic bacteria present in the blood of patients with hyperglycemia or diabetes, it was found that they can be effectively utilized in the treatment of infectious diseases in such patients.
[0180] Experimental Example 6. Identification of molecules present on the surface of red blood cell-derived magnetic immune particles that contribute to the capture of pathogenic substances
[0181] In order to identify which molecule contributes to the capture of pathogenic substances among various surface molecules containing various receptors immobilized (attached) to the cell membrane surface of red blood cell-derived magnetic immune particles, red blood cell-derived magnetic immune particles in which specific surface molecules were inactivated on the cell membrane surface were prepared and the removal rate of pathogenic substances was analyzed.
[0182] Specifically, in the red blood cell-derived magnetic immune particles prepared in Example 1 above, CR1 (complement receptor 1) and / or GYPA (glycophorin A), which are cell membrane surface molecules, were inactivated with corresponding antibodies, respectively, to obtain red blood cell-derived magnetic immune particles in which CR1 and / or GYPA were inactivated.
[0183] In addition, various pathogenic substances (MRSA, ESBL(+)) in human plasma samples E.coli, RSV, CMV, ZIKV E Protein, HCoV-OC43 (Human coronavirus OC43), or SARS-CoV-2 S Protein) were inoculated respectively (bacteria are about 10 4 Inoculate to a concentration of CFU / mL, and the virus is approximately 10 4 (Inoculated to a concentration of PFU / mL and protein to a concentration of approximately 1 μg / mL), and after injecting each of the various types of magnetic immune particles obtained above, the pathogenic substance removal rate (%) of each magnetic immune particle was measured. The specific experimental method was the same as that performed in Experimental Example 1 above, and the types of magnetic immune particles injected are as follows:
[0184] 1) Red blood cell-derived magnetic immune particles (RBC-MNVs) prepared in Example 1 above
[0185] 2) Magnetic immune particles (CR1 blocked RBC-MNVs) in which CR1, a cell membrane surface molecule, is inactivated in the red blood cell-derived magnetic immune particles prepared in Example 1 above
[0186] 3) Magnetic immune particles (GYPA blocked RBC-MNVs) in which the cell membrane surface molecule GYPA is inactivated in the red blood cell-derived magnetic immune particles prepared in Example 1 above
[0187] 4) Magnetic immune particles in which the cell membrane surface molecules CR1 and GYPA are inactivated in the red blood cell-derived magnetic immune particles prepared in Example 1 above (GYPA&CR1 blocked RBC-MNVs)
[0188] 5) Magnetic particles (MNPs) that do not contain a cell membrane surface.
[0189] As a result, as shown in Fig. 15, it was confirmed that when CR1 or GYPA, which are cell membrane surface molecules, are inactivated in the erythrocyte-derived magnetic immune particles prepared in Example 1, the removal rate of pathogenic substances by the erythrocyte-derived magnetic immune particles decreases. Specifically, when CR1, a cell membrane surface molecule, is inactivated, MRSA, ESBL(+) E.coli It was confirmed that the capture (or clearance) ability of the aforementioned erythrocyte-derived magnetic immune particles against all of the following were significantly reduced: RSV, CMV, ZIKV E Protein, HCoV-OC43, and SARS-CoV-2 S Protein, and when the cell membrane surface molecule GYPA is inactivated, MRSA, ESBL(+) E.coli It was confirmed that the capture (or removal) ability of the above erythrocyte-derived magnetic immune particles against CMV, and CMV was significantly reduced, whereas the capture (or removal) ability of the above erythrocyte-derived magnetic immune particles against RSV, ZIKV E Protein, HCoV-OC43, and SARS-CoV-2 S Protein did not change significantly. In addition, it was confirmed that the removal rate of pathogenic substances by the above erythrocyte-derived magnetic immune particles decreased the most when both CR1 and GYPA, which are cell membrane surface molecules, were inactivated. Through this, it was found that CR1 and / or GYPA (especially CR1) present on the cell membrane surface of the above erythrocyte-derived magnetic immune particles contribute significantly to the capture of pathogenic substances.
[0190] Therefore, through this experimental example, it was found that in the case of erythrocyte-derived magnetic immune particles prepared using erythrocyte-derived cell membranes in which CR1 and / or GYPA are expressed (or overexpressed), the ability to capture pathogenic substances (detection or removal ability) can be significantly increased.
[0192] Experimental Example 7. Confirmation of the effect of enhancing the pathogenic substance capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles by the addition of opsonin
[0193] The effect of enhancing the pathogenic substance capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles due to the addition of opsonin was confirmed.
[0194] Specifically, various pathogenic substances (MRSA, ESBL(+)) in TBS buffer or human blood samples E.coli Each of the following was inoculated with RSV, CMV, ZIKV E Protein, HCoV-OC43, or SARS-CoV-2 S Protein, and each of the following was added: various opsonins (MBL (mannose binding lectin), FCN-1 (Ficolin-1), FCN-2, FCN-3, CL-10 (collectin-10), CL-11, C3b, or C1q (complement component 1q)), and then the erythrocyte-derived magnetic immune particles prepared in Example 1 were injected to measure the capture rate (or removal rate, %) of pathogenic substances by the magnetic immune particles. The specific experimental method is the same as the method performed in Experimental Example 1, except that the opsonins were injected into TBS buffer or human blood samples.
[0195] As a result, as shown in Fig. 16, it was confirmed that when the opsonin of MBL or FCN-1 is injected together with the erythrocyte-derived magnetic immune particles prepared in Example 1 into a TBS buffer or human blood sample containing pathogenic substances such as pathogenic bacteria, viruses, and virus-derived antigen proteins, the pathogenic substance capture ability (detection or removal ability) of the erythrocyte-derived magnetic immune particles is significantly improved. In addition, it was confirmed that the pathogenic substance capture ability (detection or removal ability) of the erythrocyte-derived magnetic immune particles is improved when the opsonin of FCN-2, FCN-3, CL-10, or CL-11 is injected together with the erythrocyte-derived magnetic immune particles prepared in Example 1 into a TBS buffer containing pathogenic substances. However, it was confirmed that when the opsonin of C3b or C1q is injected, the level of increase in the pathogenic substance capture ability (detection or removal ability) of the erythrocyte-derived magnetic immune particles is relatively significantly lower. Through this, it was found that specific opsonins, such as MBL or FCN-1, rather than all types of opsonins, can strongly enhance the ability to capture (detect or remove) pathogenic substances of the above-mentioned red blood cell-derived magnetic immune particles.
[0196] Through this experimental example, it was found that when detecting or removing pathogenic substances (e.g., pathogenic bacteria, viruses, virus-derived antigen proteins, etc.) in a sample of an individual (e.g., blood, etc.) using erythrocyte-derived magnetic immune particles, if specific opsonins such as MBL, FCN-1, FCN-2, FCN-3, CL-10, and CL-11 (especially MBL or / and FCN-1) are additionally injected, the ability of the erythrocyte-derived magnetic immune particles to capture pathogenic substances (detection or removal ability) is further enhanced, and the effect of detecting or removing pathogenic substances in the sample and the resulting effect of diagnosing or treating infectious diseases can be further enhanced.
[0198] Experimental Example 8. Evaluation of the capture ability (detection or removal ability) of red blood cell-derived magnetic immune particles against cancer-related substances
[0199] We verified whether red blood cell-derived magnetic immune particles could capture (detect or remove) cancer-related substances present in blood samples in vitro, and analyzed the applicability of red blood cell-derived magnetic immune particles for the diagnosis, prevention, improvement, or treatment of cancer.
[0200] Specifically, extracellular vesicles derived from breast cancer cell lines, nucleic acids derived from normal cells, or nucleic acids derived from tumor cells were inoculated into human plasma or human blood samples and mixed and reacted for a certain period of time. Then, human erythrocyte-derived magnetic immune particles (or mouse erythrocyte-derived magnetic immune particles) prepared in Example 1 were injected into each sample and reacted at approximately 37°C for about 20 minutes. Afterward, the magnetic immune particles within each sample were fixed at a specific location using a magnet so that they would not be included in the supernatant, and then the supernatant was collected. The amounts of extracellular vesicles derived from breast cancer cell lines, nucleic acids derived from normal cells, or nucleic acids derived from tumor cells were measured in the supernatant, and the removal efficiency (i.e., detection rate or binding efficiency) of the magnetic immune particles for extracellular vesicles derived from breast cancer cell lines, nucleic acids derived from normal cells, or nucleic acids derived from tumor cells was measured by comparing the measured values with the amounts of extracellular vesicles derived from breast cancer cell lines, nucleic acids derived from normal cells, or nucleic acids derived from tumor cells initially inoculated into each sample.
[0201] As a result, as shown in FIGS. 17 and 18, it was confirmed that the erythrocyte-derived magnetic immune particles prepared in Example 1 bind with excellent efficiency to extracellular vesicles derived from cancer cell lines and nucleic acids derived from tumor cells present in human plasma or human blood samples. Through this, it was found that the erythrocyte-derived magnetic immune particles can detect or remove cancer-related substances, such as extracellular vesicles derived from cancer cell lines and nucleic acids derived from tumor cells present in human plasma or human blood, with excellent efficiency. In addition, the erythrocyte-derived magnetic immune particles prepared in Example 1 had a low binding rate to nucleic acids derived from normal cells but a significantly high binding rate to nucleic acids derived from tumor cells. Through this, it was found that the erythrocyte-derived magnetic immune particles can selectively capture and remove only cancer-related substances, such as extracellular vesicles derived from cancer cell lines and nucleic acids derived from tumor cells present in human plasma or human blood, and thus can be usefully utilized for cancer-specific detection, diagnosis of cancer (e.g., diagnosis of cancer metastasis or recurrence, prediction of responsiveness to cancer treatment drugs, etc.), or prevention or treatment of cancer (e.g., prevention or treatment of cancer metastasis or recurrence, improvement of responsiveness to cancer treatment drugs, improvement of cancer treatment prognosis, adjuvant treatment in combination with anticancer treatment, etc.). Furthermore, it was confirmed that both human erythrocyte-derived magnetic immune particles and mouse erythrocyte-derived magnetic immune particles bind with tumor cell-derived nucleic acids present in human blood samples with excellent efficiency, indicating that erythrocyte-derived magnetic immune particles can be applied for the detection or removal of cancer-related substances without species-specific differences.
[0202] Next, the nucleic acids derived from normal cells and tumor cells that were bound (i.e. captured) to the erythrocyte-derived magnetic immune particles prepared in Example 1 were recovered from the erythrocyte-derived magnetic immune particles using a commercially available elution solution, and the recovery rate was measured. In addition, the absorbance of the recovered nucleic acids was measured at wavelengths of 260 nm and 280 nm, and the purity of the recovered nucleic acids was analyzed using the ratio.
[0203] As a result, as shown in Fig. 19, it was confirmed that both normal cell-derived nucleic acids and tumor cell-derived nucleic acids bound (i.e., captured) to the red blood cell-derived magnetic immune particles prepared in Example 1 were recovered with an excellent efficiency of over 80% by the elution solution. Furthermore, the absorbance ratio values of the recovered nucleic acids were confirmed to be approximately 1.677 (normal cell-derived nucleic acids) and approximately 1.7 (tumor cell-derived nucleic acids), confirming high DNA purity (generally, the absorbance ratio value of pure DNA is 1.6 to 1.8). Through this, it was found that when detecting cancer-related nucleic acids, such as tumor cell-derived nucleic acids, using red blood cell-derived magnetic immune particles, the detected nucleic acids can be easily recovered with high purity, enabling molecular-level analysis such as PCR on the detected nucleic acids. Consequently, it was found that the analytical efficiency and accuracy can be further enhanced when red blood cell-derived magnetic immune particles are applied to cancer-specific detection and cancer diagnosis.
[0205] Experimental Example 9. Evaluation of the capture ability (detection or removal ability) of erythrocyte-derived magnetic immune particles against brain disease-related substances
[0206] By confirming whether red blood cell-derived magnetic immune particles can capture (detect or remove) substances related to brain diseases (e.g., Alzheimer's) present in blood samples in vitro, the applicability of said red blood cell-derived magnetic immune particles for the diagnosis, prevention, improvement, or treatment of brain diseases was analyzed.
[0207] Specifically, amyloid beta 42 (Aβ42), an Alzheimer's-related protein, was inoculated into a human blood sample and mixed and reacted for a certain period of time. Then, human red blood cell-derived magnetic immune particles prepared in Example 1 were injected into the sample and reacted at approximately 37°C for about 20 minutes. Afterward, a magnet was used to fix the magnetic immune particles within the sample to a specific location so that they would not be included in the supernatant, and the supernatant was collected. The amount of amyloid beta 42 in the supernatant was measured, and the measured value was compared with the amount of amyloid beta 42 inoculated into the initial sample to measure the removal efficiency (i.e., detection rate or binding efficiency) of the magnetic immune particles against amyloid beta 42.
[0208] In addition, after inoculating mouse blood samples with Alzheimer's-related proteins such as amyloid beta 42 (Aβ42), amyloid beta 40 (Aβ40), or tau proteins and mixing and reacting them for a certain period of time, the reacted blood samples and mouse erythrocyte-derived magnetic immune particles prepared in the same manner as in Example 1 were injected into the extracorporeal circulation device of Experimental Example 2 in the same manner as in Experimental Example 2 to perform a process of removing the Alzheimer's-related proteins from the blood samples through erythrocyte-derived magnetic immune particle-based extracorporeal blood circulation. Subsequently, the concentration of the Alzheimer's-related proteins in the discharged blood samples was measured at regular time intervals.
[0209] As a result, as shown in FIGS. 20 and 21, it was confirmed that the red blood cell-derived magnetic immune particles prepared in Example 1 and the mouse red blood cell-derived magnetic immune particles prepared by the same method both bind with excellent efficiency to amyloid beta 42, amyloid beta 40, and tau proteins present in blood samples, and through this, it was found that the red blood cell-derived magnetic immune particles can detect or remove brain disease (e.g., Alzheimer's) related substances such as amyloid beta 42, amyloid beta 40, and tau proteins present in blood with excellent efficiency. In particular, it was confirmed that by using the above-mentioned red blood cell-derived magnetic immune particle-based extracorporeal blood circulation system, tau protein present in the blood sample can be removed up to about 70% of the initial inoculation amount within about 1 hour, and amyloid beta 40 and amyloid beta 42 present in the blood sample can be removed up to about 100% of the initial inoculation amount within about 1 hour, thereby being removed to a level below the detection limit of commercially available enzyme-linked immunosorbent assay kits.
[0210] Through this experimental example, it was found that the above-mentioned red blood cell-derived magnetic immune particles can detect or remove brain disease (e.g., Alzheimer's) related substances such as amyloid beta 42, amyloid beta 40, and tau proteins present in the blood with excellent efficiency, and thus can be usefully utilized for the diagnosis, prevention, or treatment of brain diseases (e.g., Alzheimer's).
[0212] Experimental Example 10. Comparison of monodispersed magnetic immune particles and polydispersed magnetic immune particles
[0213] The capture ability (detection or removal ability) of monodispersed magnetic immune particles and polydispersed magnetic immune particles for cancer-related substances and brain disease-related substances present in in vitro blood samples was compared and analyzed.
[0214] First, monodisperse magnetic particle(s) were prepared using materials provided by BElement Inc. (South Korea). Additionally, polydisperse magnetic particle(s) were purchased and prepared (Cat: 02121, Ademtech, France). For the monodisperse and polydisperse magnetic particle(s), the particle size (diameter) distribution and polydispersity index (PDI) were measured using a Zeta size instrument (Nano ZS Zetasizer, Malvern Analytical, UK). The polydispersity index is defined as the square of the value obtained by dividing the standard deviation of the particle size (diameter) by the mean of the particle size (diameter). It has a value between 0 and 1, and values closer to 0 (e.g., approximately 0.17 or less) indicate that the particles are monodisperse particles with uniform particle sizes.
[0215] As a result, as shown in FIG. 22, the diameter distribution of the monodisperse magnetic particle(s) was measured to be between about 200 and 300 nm, and in particular, the polydispersity index was significantly low at about 0.05 or less (specifically, about 0.03 or less, about 0.02 or less, or about 0.02), confirming that the particle size was very uniform. On the other hand, the diameter distribution of the polydispersity magnetic particle(s) was measured to be between about 150 and 500 nm, and the polydispersity index was also measured to be about 0.176, confirming that the particle size was very non-uniform compared to the monodisperse magnetic particle(s).
[0216] Next, erythrocyte-derived magnetic immune particles were prepared using the monodisperse magnetic particle(s) or polydisperse magnetic particle(s) and an erythrocyte-derived cell membrane in the same manner as in Example 1. The magnetic immune particles prepared using the monodisperse magnetic particle(s) and the erythrocyte-derived cell membrane were classified as 'monodisperse magnetic immune particles,' and the magnetic immune particles prepared using the polydisperse magnetic particle(s) and the erythrocyte-derived cell membrane were classified as 'polydisperse magnetic immune particles.'
[0217] In addition, extracellular vesicles derived from breast cancer cell lines, nucleic acids derived from normal cells, nucleic acids derived from circulating tumor cells, amyloid beta 42, amyloid beta 40, or tau protein were inoculated into human blood samples and mixed and reacted for a certain period of time. After that, the monodisperse magnetic immune particles and polydisperse magnetic immune particles were injected into each of the samples, respectively, and after reacting at about 37°C for about 20 minutes, the magnetic immune particles within each sample were fixed at a specific location using a magnet so that the magnetic immune particles were not included in the supernatant, and then the supernatant was collected. The amount of extracellular vesicles derived from the breast cancer cell line, nucleic acids derived from normal cells, nucleic acids derived from circulating tumor cells, amyloid beta 42, amyloid beta 40, or tau protein in the supernatant was measured, and the removal efficiency (i.e., detection rate or binding efficiency) of the magnetic immune particles for extracellular vesicles derived from the breast cancer cell line, nucleic acids derived from normal cells, nucleic acids derived from circulating tumor cells, amyloid beta 42, amyloid beta 40, or tau protein was measured by comparing the measured value with the amount initially inoculated into each sample.
[0218] As a result, as shown in FIG. 23, it was confirmed that the monodisperse magnetic immune particles bind with excellent efficiency to nucleic acids derived from circulating tumor cells and extracellular vesicles derived from cancer cell lines present in human blood samples, and that the binding rate to nucleic acids derived from circulating tumor cells is significantly higher than the binding rate to nucleic acids derived from normal cells. Through this, it was found that the monodisperse magnetic immune particles can specifically capture cancer-related substances present in human blood and detect or remove them with high efficiency. In particular, it was confirmed that the monodisperse magnetic immune particles exhibit significantly superior capture ability (detection ability or removal ability) for cancer-related substances compared to the polydisperse magnetic immune particles.
[0219] In addition, as shown in FIG. 24, it was confirmed that the monodisperse magnetic immune particles bind with amyloid beta 42, amyloid beta 40, and tau proteins present in human blood samples with excellent efficiency. Through this, it was found that the monodisperse magnetic immune particles can capture substances related to brain diseases (e.g., Alzheimer's) present in human blood and detect or remove them with high efficiency. In particular, it was confirmed that the monodisperse magnetic immune particles exhibit superior capture ability (detection ability or removal ability) for substances related to brain diseases (e.g., Alzheimer's) compared to the polydisperse magnetic immune particles.
[0220] Through this experimental example, it was found that red blood cell-derived magnetic immune particles prepared using monodisperse magnetic particle(s) with a higher degree of particle size uniformity exhibited superior capture ability (detection ability or removal ability) for cancer-related substances and brain disease-related substances compared to red blood cell-derived magnetic immune particles prepared using polydisperse magnetic particle(s).
[0222] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments and experimental examples described above should be understood as illustrative in all respects and not restrictive.
Claims
Claim 1 Cell membrane derived from red blood cells; A magnetic immune particle comprising iron oxide magnetic particles having an average particle size of 100 nm to 1000 nm attached to the cell membrane, wherein the magnetic immune particle comprises an outer surface comprising the cell membrane and an inner core comprising the magnetic particles, wherein the cell membrane comprises one or more selected from the group consisting of a complement receptor (CR), a cluster of differentiation (CD) molecule, a glycophorin, a Duffy antigen receptor for chemokines (DARC), a glucose transporter, and a monocarboxylate transporter, wherein the magnetic particles are monodisperse magnetic particles having a polydispersity index (PDI) of 0.17 or less, and wherein the magnetic immune particle is obtained by extrusion and ultrasonographic treatment of a mixture of a red blood cell or a cell membrane separated from a red blood cell and magnetic particles. Claim 2 In claim 1, the magnetic particles are from the group consisting of iron (Fe), nickel (Ni), cobalt (Co), manganese (Mn), bismuth (Bi), zinc (Zn), strontium (Sr), lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), ruthenium (Lu), copper (Cu), silver (Ag), gold (Au), cadmium (Cd), mercury (Hg), aluminum (Al), gallium (Ga), indium (In), thallium (Tl), calcium (Ca), barium (Ba), radium (Ra), platinum (Pt), and lead (Pd). A magnetic immune particle comprising one or more selected magnetic elements. Claim 3 delete Claim 4 A magnetic immune particle according to claim 1, wherein the cell membrane has the form of a vesicle. Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 delete Claim 10 delete Claim 11 A composition comprising a magnetic immune particle according to any one of claims 1, 2, and 4, wherein the composition is intended to detect or remove one or more selected from the group consisting of pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances, wherein the pathogenic substance comprises one or more selected from the group consisting of bacteria, fungi, viruses, parasites, prions, and toxins, and the inflammatory cytokines include tumor necrosis factor-α (TNF-α), Interleukin 4 (IL-4), Interleukin 6 (IL-6), Interleukin-1 beta (IL-1β), Interleukin-1 alpha (IL-1α), Interleukin 8 (IL-8), Interferon gamma (IFN-γ), and A composition comprising one or more selected from the group consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF), wherein the cancer-related substance comprises cancer cells, extracellular vesicles derived from cancer cells, nucleic acids derived from cancer cells, or a combination thereof, and wherein the brain disease-related substance comprises amyloid beta (Aβ) protein, tau protein, or a combination thereof. Claim 12 delete Claim 13 delete Claim 14 delete Claim 15 delete Claim 16 A composition for diagnosing a disease comprising a magnetic immune particle of any one of claims 1, 2, and 4, wherein the disease is an infectious disease, an inflammatory disease, diabetes, cancer, or a brain disease. Claim 17 A method for detecting or removing from a sample one or more substances selected from the group consisting of pathogenic substances, inflammatory cytokines, blood glucose, cancer-related substances, and brain disease-related substances present in the sample, comprising: a step of mixing the sample by contacting it with the magnetic immune particles of any one of claims 1, 2, and 4; and a step of applying a magnetic field to the mixed sample; wherein the method further comprises a step of introducing opsonin prior to the step of applying the magnetic field, and wherein the method is performed by an extracorporeal blood circulation device. Claim 18 delete Claim 19 delete Claim 20 A method for providing information necessary for the diagnosis of a disease, comprising: a step of mixing a sample separated from an individual by contacting a magnetic immune particle of any one of claims 1, 2, and 4 with the sample; and a step of applying a magnetic field to the mixed sample, wherein the disease is an infectious disease, an inflammatory disease, diabetes, cancer, or a brain disease, and the method further comprises a step of introducing opsonin prior to the step of applying the magnetic field, and the method is performed by an extracorporeal blood circulation device. Claim 21 delete Claim 22 delete Claim 23 delete Claim 24 delete Claim 25 delete Claim 26 A method for producing magnetic immune particles comprising: a step of mixing a red blood cell or a cell membrane separated from a red blood cell with magnetic particles; and a step of extruding or ultrasonically treating the mixture obtained in the mixing step, wherein the magnetic particles are iron oxide magnetic particles having an average particle size of 100 nm to 1000 nm, and the magnetic immune particles comprise an outer surface including the cell membrane and an inner core including the magnetic particles, and the cell membrane comprises one or more selected from the group consisting of a complement receptor (CR), a cluster of differentiation (CD) molecule, a glycophorin, a Duffy antigen receptor for chemokines (DARC), a glucose transporter, and a monocarboxylate transporter, and the magnetic particles are monodisperse magnetic particles having a polydispersity index (PDI) of 0.17 or less. Claim 27 delete Claim 28 delete
Citation Information
Patent Citations
LOX and LOXL2 inhibitors and uses thereof
JP2017214361A
Magnetic Immuno-Particle and Use thereof
KR1020190103819A
Erythrocyte membrane coated magnetic nanoparticles as well as preparation method and application thereof
CN113476603A
Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015021390A2
